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	Abstract  
     There are few recommendations on how best to apply certain modes of mechanical 
ventilation.  The application of Airway Pressure Release Ventilation (APRV) includes strategic 
implementation of specific inspiratory times (I-times) and particular mean airway pressures 
(MAWP) neither of which is standardized.  This study utilized a retrospective analysis of 
archived electronic health record data to evaluate the clinical outcomes of adult patients that had 
been placed on APRV for at least 8 hours.  68 adult subjects were evaluated as part of a 
convenient purposive sample.  All outcomes of interest (surrogates) for short-term clinical 
outcomes to include the PaO2/FiO2 (P/F) ratio, Oxygen Index and Oxygen Saturation Index (OI; 
OSI), and Modified Sequential Organ Failure Assessment (MSOFA) scores showed 
improvement after at least 8 hours on APRV.  Most notably, there was significant improvement 
in P/F ratio (p = .012) and OSI (p = .000).  Results of regression analysis showed P low as a 
statistically significant negative predictor of pre-APRV P/F ratio with a higher initial P low 
coinciding with a lower P/F ratio.  The regression analysis also showed MAWP as a significant 
positive predictor of post-APRV OSI and P high and P low as significant negative predictors of 
post-APRV MSOFA scores.  In summary, it was found that settings for P high, Plow, and T low 
in addition to overall MAWP and Body Mass Index (BMI) had significant correlation to impact 
at least one of the short-term clinical outcomes measured.  
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Chapter 1: Introduction 
Introduction to Chapter 1 
 Millions of patients are hospitalized in the U.S. each year, and roughly 3% of all who are 
admitted to an acute care institution will require positive pressure ventilation (PPV) (Wunsch et 
al., 2010).  In an intensive care environment, there are multiple approaches to artificially 
ventilating patients, and the means by which a patient is ventilated is well-known to affect the 
patient’s course of care and, most importantly, outcomes (Serpa Neto, Cardoso, Manetta, & et 
al., 2012).  It has been established that PPV is anti-physiologic and contributes to morbidity and 
mortality under certain conditions (A. Esteban et al., 2013).  Furthermore, there is a correlation 
between ventilation volume, airway pressure, and the development of ventilator-induced lung 
injury (VILI) ("Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal 
Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome," 2000). 
Although recent animal studies have attempted to establish a type of strain threshold at 
which lung damage occurs, there is lacking evidence as to which entity—dynamic strain (such as 
volutrauma) or static strain (such as barotrauma)—primarily contributes to principal lung injury 
(Protti et al., 2013; Protti et al., 2011).  Volutrauma, caused by generalized lung overdistention, 
and barotrauma, caused by high transpulmonary pressures, are each known to contribute to 
overall VILI (Beitler, Malhotra, & Thompson, 2016), but it may be the avoidance of 
atelectrauma, which is caused from cyclic opening and closing of the lung, that is most effective 
in VILI prevention (Cressoni et al., 2017).  Some studies suggest that an open lung approach is 
ideal because it prevents atlectrauma (Cressoni et al., 2017).  Additionally, the management of 
specific mean airway pressures (MAWP) is more protective than the traditional approach of 
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targeting conservative inspiratory volumes (Kacmarek, Villar, et al., 2016).  However, there is no 
consensus regarding how best to specifically apply pressure modes of PPV.     
Airway Pressure Release Ventilation (APRV), in particular, is a mode of PPV that offers 
an alternative to conventional ventilation strategies.  Moreover, in several small-scale, 
observational studies, PPV with APRV has been shown to improve overall oxygenation and 
allow a shorter intensive care unit stay with fewer days on the ventilator (E. G. Daoud, H. L. 
Farag, & R. L. Chatburn, 2012).  Specifically, APRV mode allows for sustained inflation of the 
lung over a more prolonged period than other pressure modes of PPV (E. G. Daoud et al., 2012), 
resulting in less cyclic opening and closing of lung units (E. G. Daoud et al., 2012; Habashi, 
2005; Protti et al., 2013).  In this chapter, the investigator will highlight the need for further 
study in this arena as well as certain proposed steps in which to accomplish the study.  
Additionally, the investigator will outline individual entities relating to the study plan and the 
execution thereof.   
Background and Statement of the Problem 
It has been estimated that nearly 3% of all hospitalized patients will receive invasive 
mechanical ventilation, and the mortality rate is significant for this population due, in part, to the 
development of VILI (A. S. Slutsky & Ranieri, 2014; Wunsch et al., 2010).  There are multiple 
factors that contribute to VILI, and neither open lung approach or conservative volume 
ventilation strategies absolutely prevent the development of this detrimental condition.  Of the 
variety of PPV strategies that seek to minimize incidence of lung injury, it has been established 
that protective ventilation, minimizing lung stretch by managing mean airway pressure, is 
preferred over traditional volume targeted ventilation (Curley, Laffey, Zhang, & Slutsky, 2016). 
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 Although temporary PPV is a common, potentially life-saving, modality, clinicians must 
recognize that it is one that poses significant risks (A. s. Esteban et al., 2013; Klompas, 2013; 
Arthur S. Slutsky & Ranieri, 2013).  However, there is little published data on recommendations 
of exactly how to implement specific ventilator modes.  Moreover, there remains a gap in 
knowledge of how to manage the continual application of certain modes of PPV.  Pressure 
targeted modes of mechanical ventilation, albeit part of a protective lung strategy (Rittayamai et 
al., 2015), require the healthcare provider to maintain astute awareness of the dynamics of 
pressure application during breath delivery.   
Multiple studies have suggested that the cyclic recruitment and de-recruitment of lung 
units, known as atelectrauma, are a primary cause of acute lung injury (ALI) with detrimental 
outcomes (Chiumello et al., 2008; Cressoni et al., 2017; Serpa Neto et al., 2012; Arthur S. 
Slutsky & Ranieri, 2013; "Ventilation with Lower Tidal Volumes as Compared with Traditional 
Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome," 2000).  
However, almost no data exists as to the specific means in which to minimize this distinctive sort 
of lung stress and strain.  Both open lung approach and conservative tidal volume ventilation are 
preferred in patients with Acute Respiratory Distress Syndrome (ARDS) (Kacmarek, Villar, et 
al., 2016; "Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes 
for Acute Lung Injury and the Acute Respiratory Distress Syndrome," 2000); however, no 
definitive ideal mode of PPV exists for all patients. 
It has been suggested that judicious use of positive end-expiratory pressure (PEEP) and 
inspiratory-to-expiratory ratios of 1:1 or greater, also considered inverse-ratio ventilation (IRV), 
can be useful in minimizing lung damage during PPV attributed to prolonged inflation times and 
de-recruitment prevention (Ehab G. Daoud, Hany L. Farag, & Robert L. Chatburn, 2012; Spieth 
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et al., 2015), and the APRV mode of PPV is one method to protectively ventilate a variety of 
patient populations that may require IRV (Burchardi, 1996; Diaz et al., 2011; Francesca Facchin, 
2015; Kollisch-Singule et al., 2014).  There is no consensus, however, as to the specific means 
by which IRV should be applied, since several studies that utilize animal or mathematical models 
have been inconclusive (Daoud & Chatburn, 2014; Arthur S. Slutsky & Ranieri, 2013). 
Relevance, Significance, and Study Purpose  
In acute care, the respiratory therapist (RT) is charged with caring for and managing 
patients that are placed on mechanical ventilation, also known as PPV.  Among physicians and 
RTs alike, there is varying opinion regarding the best means in which to artificially ventilate 
patients, as there are many choices in mode, breath delivery, and various other parameters that 
can be controlled by the operator of the PPV machine.  Numerous studies address the nature of 
PPV and overall clinical implications; however, few have identified specific strategies that 
effectively allow patients to be mechanically ventilated, short-term, while protecting against 
VILI.   
 At the turn of the century, one paramount study ("Ventilation with Lower Tidal Volumes 
as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory 
Distress Syndrome," 2000) established that lower tidal volumes are preferred to higher tidal 
volumes during PPV; however, end inspiratory pressure must also be considered to prevent VILI 
(Protti et al., 2011).  A substantial number of patients placed on PPV are ventilated using a type 
of pressure-controlled mode, rendering volume to be a function of the particular pressure applied 
and the overall pulmonary mechanics.  Both volume and pressure modes of PPV offer 
advantages individually; however, modes of PPV in which pressure is controlled has gained 
favor as a means to employ a protective lung strategy (Rittayamai et al., 2015).  The APRV 
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mode, specifically, offers a variety of options that will manipulate breath delivery while 
absolutely controlling the application of pressure during the breath cycle, which is also 
considered a mode of PPV recommended for patients with already developing or concomitant 
lung injury (Burchardi, 1996; E. G. Daoud et al., 2012; J. B. Downs & Stock, 1987). 
 Mechanical ventilation via PPV has long been known to induce ALI and contribute to 
overall morbidity and mortality in acute care patients (de Prost, Ricard, Saumon, & Dreyfuss, 
2011).  As ventilation strategies and modes of PPV have evolved, there has been little 
improvement in overall incidence of ALI and associated mortality rates (Erickson, Martin, 
Davis, Matthay, & Eisner, 2009; A. Esteban et al., 2013).  The current fourth generation 
mechanical ventilators allow for more autonomy in delivering positive pressure breaths. 
However, this increased capability requires more decision-making when implementing a modern 
mode of PPV.  Because PPV poses significant risk, regardless of the mode (Rittayamai et al., 
2015), clinicians must remain perspicacious when seeking both to prevent and treat VILI as well 
as ALI.  
 Although, microprocessor-controlled, later-model ventilators are more sensitive to patient 
biofeedback, improperly implemented modes of PPV can have deleterious effects on the lung (de 
Prost et al., 2011).  Clinicians are able to apply and limit specific ventilation pressure and 
maintain relative control of many aspects of the breath cycle (Kacmarek, 2011), yet there are 
many variables to consider in order to ventilate safely a multiplicity of patient populations.  
From the advent of PPV in the early 1900s to the current versions of microprocessor-
controlled machines with graphical user interface, mechanical ventilation has changed 
dramatically (Kacmarek, 2011).  With advancements in PPV breath delivery options, various 
modes of mechanical ventilation have been introduced that allow clinicians more choices in how 
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the respiratory cycle can be manipulated (Tobin, 2001).  More is also known regarding what 
contributes to VILI.  However, a significant portion of mechanically ventilated patients are still 
developing VILI, occasionally described as ALI or vent-propagated Acute Respiratory Distress 
Syndrome (ARDS) (Erickson et al., 2009).  Unfortunately, there is disagreement concerning the 
application of certain modes of PPV, and mortality attributed to mechanical ventilation remains 
high (Erickson et al., 2009; A. Esteban et al., 2013). 
 As is it difficult to quantify actual lung stress and strain during PPV, the evaluation of 
plateau pressure and tidal volumes are considered the surrogates for assessing this metric 
(Chiumello et al., 2008), and a protective lung strategy remains the preferred approach to 
minimize stress and strain (Rittayamai et al., 2015).  In order to prevent VILI, tidal volumes must 
be kept within an acceptable range, lower than 6 ml/kg of predicted body weight (Serpa Neto et 
al., 2012; "Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes 
for Acute Lung Injury and the Acute Respiratory Distress Syndrome," 2000), and the 
recommended plateau pressure should be maintained lower than 30 cmH20 (de Prost et al., 
2011).   
 A special type of pressure-targeting mode, APRV, promotes an open lung concept 
(Lachmann, 1992) and is considered to be part of a protective lung strategy in the application of 
PPV (E. G. Daoud et al., 2012; Tobin, 2001).  Although APRV permits the clinician to maintain 
a consistent plateau pressure, there is no consensus, or established guideline, with respect to the 
safest threshold for the absolute prevention of ALI (Rittayamai et al., 2015).  It is also unknown 
whether APRV mode employed with higher inspiratory times (I-times) and lower plateau 
pressures results in better clinical outcomes when compared to APRV mode employed with 
shorter I-times and higher plateau pressures.   
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This study investigated association between various settings in the APRV mode and short 
term clinical outcomes of interest.  Because there is a general lack of data as to what specific I-
times and sustained pressures allow for maximal oxygenation and best short term outcomes, this 
study sought to distinguish whether there is a superior way in which to implement and manage 
the APRV mode of PPV.  If specific settings are associated with better clinical outcomes, 
clinicians should be able to initiate more purposefully the APRV mode for patients prior to the 
development of VILI.  Likewise, as the study revealed certain predictors of clinical outcomes, 
the findings will hopefully stimulate further study into this area, allowing for more standard 
initial PPV setting recommendations for patients that will receive APRV or for those patients 
who have already developed ALI or ARDS. 
Elements 
Hypotheses 
Overall, in APRV mode, the use of a longer I-time results in ideal mean airway pressure, 
less pulmonary stress and strain due to less cyclic opening and closing of the lung, and, 
therefore, overall better clinical outcomes as evidenced by better PaO2/FiO2 ratio, Oxygenation 
Index (OI), Oxygen Saturation Index (OSI), and Modified Sequential Organ Failure Assessment 
(MSOFA) scores when compared to the use of shorter I-times in a similar patient population.   
H0: There is no relationship between the length of I-time and short-term clinical outcomes, such  
as PaO2/FiO2 ratio, OI, OSI, and MSOFA scores. 
H1: If there is a relationship between the length of I-time and short-term clinical outcomes, 
patients ventilated with longer I-times will demonstrate better short-term clinical 
outcomes, as evidenced by better P/F ratio, OI, OSI, and MSOFA scores, than patients 
ventilated with shorter I-times because of the application of ideal mean airway 
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pressures. 
Theories  
The theoretical framework that guided this research is founded in the evidence-based 
medicine model of best clinical practice ("Evidence-based Medicine. A new Approach to 
Teaching the Practice of Medicine," 1992).  Moreover, the investigator sought to integrate the 
theory of evidence-based medicine into bedside clinical practice (K. Walshe & T. G. Rundall, 
2001) through the adoption of the presupposition that if an intervention or therapy is shown to 
improve the overall course of care of a large group of similar patients, then that particular 
intervention or therapy should be considered as best practice in a similar patient population, 
provided that no other published data suggests the antithesis.  Walshe and Rundall (2001) 
highlighted the fact that there exists relatively unexplained, eclectic variations in clinical 
practice patterns, and, for decades, evidence has been produced that emphasizes this gap 
between research and clinical practice.  This study sought to allow a translation of research into 
bedside clinical practice.   
 In a review by Tabak et al. (Tabak, Khoong, Chambers, & Brownson, 2012), 61 
different models of current theories and frameworks were evaluated for specific modalities of 
dissemination and implementation of research into practice.  Unfortunately, available measures 
to confirm implementation of any research is generally lacking given the broad spectrum of a 
particular application in various settings.  Additionally, the general small sample size of 
numerous studies may hamper the overall development, evaluation, and use of standard 
measures (Tabak et al., 2012). 
 Upon study conclusion, the investigator adopted an analogous model for disseminating 
and implementing the study results as originally proposed by Funk, Tornquist, and Champagne 
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(Funk, Tornquist, & Champagne, 1989).  Furthermore, as most dissemination practices lack 
consistency and broad impact, it would be important to mimic an already established model 
type of persuasive communication, or diffusion, of innovation as cited in a review by Wilson et 
al. (Wilson, Petticrew, Calnan, & Nazareth, 2010). 
Research Question 
Do patients ventilated with longer I-times, in APRV mode, have better short-term clinical 
outcomes compared to patients ventilated in the same mode with shorter I-times?  These so-
called short-term clinical outcomes will encompass a variety of metrics to include P/F ratio, OI, 
OSI, and MSOFA score (Dechert, Park, & Bartlett, 2014; Ferreira, Bota, Bross, Melot, & 
Vincent, 2001; Grissom et al., 2010; Rawat et al., 2015; Vincent et al., 1996).  The investigation 
of long-term clinical outcomes is of interest; however, it was not investigated during this study 
since a retrospective analysis of archived EHR data does not allow for long-term follow-up or 
confirmation of post hospital stay mortality. 
Definition of Terms 
Conceptual 
 All of the following definitions have been extracted from Egan’s Fundamentals of 
Respiratory Care (Kacmarek, Stoller, & Heuer, 2016) and may be further defined in the 
following “Operational” section.   
Airway-Pressure Release Ventilation (APRV) – form of pressure ventilation that uses two levels 
of continuous positive airway pressure in an intermittent mandatory ventilation breathing pattern 
Barotrauma – physical injury sustained as a result of exposure to ambient pressures above 
normal, most commonly secondary to positive pressure ventilation (e.g. pneumothorax and 
pneumomediastinum) 
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Positive End-Expiratory Pressure (PEEP) – application and maintenance of pressure above 
atmospheric at the airway throughout the expiratory phase of positive pressure mechanical 
ventilation 
Ventilator-induced lung injury (VILI) – lung injury which occurs as a result of excessive 
pressure and/or volume during mechanical ventilation 
Volutrauma – alveolar overdistention and damage caused by ventilation with high peak inflation 
pressures 
Operational 
Airway-Pressure Release Ventilation (APRV) –  a specific mode of PPV, originally described by 
in 1987 (J. B. Downs & Stock, 1987) as a type of continuous positive airway pressure (aka 
CPAP) in which unusually long I-times are utilized at higher held pressure levels 
Barotrauma – lung injury caused by the delivery of excess pressure during PPV 
Inverse Ratio Ventilation (IRV) – inspiratory times during PPV that exceed expiratory times, 
typically in order to increase mean airway pressure at lower peak distending pressures 
Positive End-Expiratory Pressure (PEEP) – above ambient pressure applied to the lung that 
persists during a resting state, at end exhalation during PPV 
Positive Pressure Mechanical Ventilation (PPV) – above ambient pressure applied to the 
airway/lungs during artificial mechanical respirator use  
Ventilator-induced lung injury (VILI) – lung damage, typically qualified by the presence of 
pulmonary edema on chest x-ray or clinical presentation that develops during and as a 
consequence of PPV 
Volutrauma – lung injury caused by the delivery of excess volume during PPV 
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Description of Variables 
Dependent 
 This study included dependent variables indicative of certain short-term clinical 
outcomes after being placed on mechanical ventilation in the APRV mode for at least 8-24 hours.  
These dependent variables were comprised of changes in the following variables between the 
time of APRV implementation and at least 8-24 hours thereafter: P/F ratio, OI, OSI, and MSOFA 
score (Dechert et al., 2014; Ferreira et al., 2001; Grissom et al., 2010; Rawat et al., 2015; 
Vincent et al., 1996).   
Independent 
 This study included many independent variables as a function of each patient’s already 
executed course of care.  These variables included:  
1) patient demographics such as: age, sex, race, height, weight, and diagnosis 
2) specific unit of care 
3) time from intubation to initiation of APRV 
4) total continuous duration on APRV 
5) variables immediately prior to being placed on APRV such as: 
• inhaled fractional concentration of oxygen (FiO2) 
• mean airway pressure (MAWP) 
• arterial partial pressure of oxygen (PaO2) 
• oxygen saturation (SaO2 or SpO2) 
• pre-APRV ventilator mode 
6) APRV initial settings such as:  
• time high (T high) 
	 12	
• pressure high (P high) 
• time low (T low) 
• pressure low (P low) 
• pressure support (PS) 
• APRV average tidal volume (Vt) 
• PS average Vt 
7) conditions at initiation of APRV such as:  
• Glasgow coma scale (GCS) 
• bilirubin 
• mean arterial pressure (MAP) 
• creatinine (Cr) 
8) APRV settings after at least 8 hours to include:  
• time high (T high) 
• pressure high (P high) 
• time low (T low) 
• pressure low (P low) 
• pressure support (PS) 
• APRV average tidal volume (Vt) 
• PS average Vt 
Covariates 
 Several covariates should be considered in a retrospective study of this type to include: 
comorbid conditions and/or differential diagnoses that may alter the course of care outside of the 
original respiratory failure as well as the following: 1) time delay to APRV, 2) individual settings 
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on APRV, 3) primary and secondary diagnoses, 4) unit of management (SICU, MICU, 
NeuroICU, Other), and 5) total continuous duration on APRV.  The presence and progression of 
organ failure as it relates separately to metrics such as the MSOFA score (Ferreira et al., 2001; 
Grissom et al., 2010; Vincent et al., 1996) as well as the model of ventilator used are also 
considered covariates. 
Rationale 
 Downs and Stock introduced a newer mode of PPV, APRV, to the healthcare market 
circa 1987.  The original study was small (N = 10) and utilized animal models (dogs), comparing 
APRV with one other traditional mode of PPV.  As a novel approach to applying Continuous 
Positive Airway Pressure (CPAP), the findings suggested that APRV was a viable mode to treat 
ALI, because arterial oxygenation improved and peak airway pressures were maintained at a 
lower level than a more traditional mode (J. B. Downs & Stock, 1987).  The next year, the same 
group conducted the first human trial of APRV with similar findings; patients with ALI were 
successfully ventilated at lower peak airway pressures when compared to traditional PPV 
(Garner, Downs, Stock, & Rasanen, 1988).  A patent was issued to Dr. Downs the same year for 
his invention of the new PPV mode (J.B. Downs, 1988). 
 After two landmark studies were published (J. B. Downs & Stock, 1987; Garner et al., 
1988), multiple variable studies were conducted to evaluate the efficacy of APRV.  Eventually, 
APRV was established as a means for implementing a protective lung strategy for the non-
injured lung as well as a recommended early treatment for ALI or ARDS (Habashi, 2005; 
Varpula et al., 2004).  There are no studies, however, that have evaluated specific I-times and the 
relationship between the resulting MAWP and short-term clinical outcomes.   
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Assumptions 
 Certain assumptions were made in order to proceed with this study, resulting in study 
validity and continuing relevance as well as application to bedside care.  To begin, as this study 
employed a retrospective analysis of archived EHRs, the investigator assumed the information 
technology (IT) department extraction team had adequately surveyed the entire UH EHR in order 
to acquire the particular purposive sample that met inclusion criteria.  Although seemingly a 
limitation, the investigator further assumed that the archived EHR data was entered into the 
medical record in its original form by each clinician and/or healthcare provider in an accurate 
manner for each individual patient, yielding the data as such.  The data extracted was raw data 
and treated as such.     
 In broader terms, various pragmatic assumptions were considered.  As PPV has been 
utilized for many years (Kacmarek, 2011), one would assume that this means of artificial 
ventilation will continue.  Additionally, after almost three decades, the APRV mode persists and 
is currently being used in the local Shreveport/Bossier City, Louisiana area with success.  
Nevertheless, APRV mode use is not prevalent across the US and is mainly used as a rescue 
mode only (E. G. Daoud et al., 2012).  There is an assumption that if evidence-based data were 
presented to suggest that the APRV mode could be utilized in a certain manner to influence 
positive clinical outcomes, more institutions would adopt this mode of PPV as an adjunct to 
standard of care (K. Walshe & T. Rundall, 2001).    
Summary 
 In summary, the investigator sought to identify certain clinical implications of longer I-
times compared to shorter I-times in APRV mode, examining specific metrics considered 
surrogates for clinical outcomes as previously described.  This retrospective study was conducted 
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via a partnership between Louisiana State University Health Sciences Center in Shreveport 
(LSUHSC-S) and University Health (UH) Hospital and may offer clinicians practical insight as 
to the best means in which to mechanically ventilate ventilate patients in a mode such as APRV, 
providing additional awareness to the specific application of PPV in order to assist patients who 
have already developed VILI.   
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Chapter 2: Review of the Literature 
  Introduction to Chapter 2 
 The implementation and management of mechanical ventilation are complex processes 
with no current standard across the medical disciplines.  Although much data exists on its use, a 
majority of studies only describe PPV as implemented within the categorical application of the 
generically controlling either volume or pressure (Rittayamai et al., 2015; A. S. Slutsky & 
Ranieri, 2014; Tobin, 2001).  Since current, fourth generation mechanical ventilators offer 
numerous modes, it is imperative that the clinician managing PPV be aware of the potential 
deleterious effects specific modes can have, whether used in the short-term or over longer 
periods.  It has been proposed that future mechanical ventilators will offer decision support 
(Kacmarek, 2011), but, currently, the physician and RT are the primary decision makers in the 
application and management of PPV.  A review of the literature reveals a convoluted plethora of 
animal studies, various recommendations, and overall disagreement related to the use of PPV.    
From the advent of PPV in the early 1900s to the current versions of microprocessor-
controlled machines with graphical user interface, mechanical ventilation has changed 
dramatically (Kacmarek, 2011).  Using advancements in PPV breath delivery options, various 
modes of mechanical ventilation have been introduced that allow clinicians more choices in how 
the respiratory cycle can be manipulated (Tobin, 2001).  More is also known as to what 
contributes to VILI.  However, a significant portion of mechanically ventilated patients are still 
developing VILI, occasionally described as ALI or vent-propagated ARDS (Erickson et al., 
2009), and agreement is lacking in how certain modes of PPV should be applied.  Furthermore, 
mortality attributed to mechanical ventilation remains high (Erickson et al., 2009; A. Esteban et 
al., 2013). 
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 As is it difficult to quantify actual lung stress and strain during PPV, the evaluation of 
plateau pressure and tidal volumes is considered the generic surrogates for assessing this metric 
(Chiumello et al., 2008), and a protective lung strategy remains the preferred approach to 
implementation and execution of PPV (Rittayamai et al., 2015).  In order to prevent VILI, tidal 
volumes must be kept within an acceptable range, lower than 6 ml/kg of predicted body weight 
(Serpa Neto et al., 2012; "Ventilation with Lower Tidal Volumes as Compared with Traditional 
Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome," 2000) with 
a recommended plateau pressure maintained lower than 30 cmH2O (de Prost et al., 2011).  
Several traditional volume-targeting modes of mechanical ventilation permit the controlled 
application of flow to deliver a, so-called, safe volume, while other traditional pressure-targeting 
modes utilize the application of pressure to achieve variable volumes with consistent plateau 
pressures (Rittayamai et al., 2015).  
 A special type of pressure-targeting mode, APRV, promotes an open lung concept 
(Lachmann, 1992) and is considered a part of a protective lung strategy of PPV (E. G. Daoud et 
al., 2012; Tobin, 2001).  Although APRV permits the clinician to manage a consistent plateau 
pressure, there is no consensus, or established guideline, as to the safest threshold in the absolute 
prevention of ALI (Rittayamai et al., 2015).  It is also unknown whether APRV mode employed 
with higher I-times and lower plateau pressures has better clinical outcomes than if utilized with 
shorter I-times and higher plateau pressures.   
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Historical Overview 
Mechanical Ventilation  
Mechanical ventilation, in its modern form, has been a mainstay of healthcare since the 
early 1900s and has developed into the fourth generation of microprocessor-controlled machines 
in common use today (Kacmarek, 2011; A. S. Slutsky, 2015).  Some might contest that the first 
account of artificial respiration is found in the antiquity of the Holy Bible’s 2 Kings 4:34, in 
which it is noted, “Then he [Elisha] went up and lay on the child, putting his mouth upon his 
mouth…  the flesh of the child became warm” (New Living Translation).  Historically, artificial 
respiration by means of PPV can be traced back in the scientific literature to Vesalis’ 1543 De 
Humani Corporis Fabrica treatise on anatomy in which he recorded:  
But that life may be restored to the animal, an opening must be attempted in the trunk of 
the trachea, into which a tube of reed or cane should be put; you will then blow into this, 
so that the lung may rise again and take air. (Singer, 1943) 
Robert Hook further expanded the knowledge of PPV through his canine experiments in which 
he explains, in detail, the use of PPV via bellows for successful resuscitation (Hook, 1666). 
During the 1700s, several paramount physiologic discoveries, including that of oxygen 
and its use in respiration, temporarily altered the view of mouth-to-mouth resuscitation 
modalities (A. S. Slutsky, 2015), but a century later saw the advent of the precursor to our most 
common form of PPV.  Circa 1864, Alfred Jones invented one of the first negative pressure 
ventilators (Jones, 1864), which would become the template for the “iron lung” that was 
originally introduced by Alfred Willez in 1876, also known as the “spirophore” (Emerson & 
Loynes, 1978).  In 1929, Drinker and Shaw developed the first widely used iron lung, originally 
purposed to treat patients with polio (Drinker & Shaw).   
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As of the 1940s, negative pressure ventilation was mainstream, but this would soon 
change when the polio resurgence reached its peak during the 1950s.  Famously, Bjorn Ibsen is 
credited with leading the charge to convert patients from negative pressure ventilation to PPV.  
Incidentally, this led to the formation of intensive care units, resembling what is known today 
(Anaethesia and the Practice of Medicine: Historical Perspectives, 2007).   
Mechanical ventilation during the polio epidemic of the mid-twentieth century still 
employed negative pressure, but this was soon replaced with PPV as a mainstay of care.  
Currently, almost all critically-ill patients requiring respiratory support will be placed on some 
form of PPV.  Of the multiplicity of various mechanical ventilators and modes of PPV, there 
remains little consistency in how PPV is applied and almost no consensus in how to manage this 
life-saving, yet anti-physiologic, intervention.   
VILI  
 It has long been known that artificial respiration, especially via PPV, can cause injury.  In 
1744, it was first described that mouth-to-mouth was preferred above the use of bellows as 
Fothergill noted, “the lungs of one man may bear, without injury, as great a force as those of 
another man can exert; which by the bellows cannot always be determined”  (Fothergill, 1744).  
During the polio epidemic, investigators recognized that PPV could induce damage to lung 
structure (Avignon, Hedenstrom, & Hedman, 1956).  The term “respirator lung” was eventually 
coined in 1967 to describe the development of “heavy lungs” that resulted from certain post 
mortem pathological findings in patients that had undergone PPV ("Respirator Lung Syndrome," 
1967).  It is now better understood that PPV is not only deleterious to the lung but can also result 
in widespread harm to other organ systems as a result of PPV-induced inflammation (Plotz, 
Slutsky, van Vught, & Heijnen, 2004).    
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A paradigm shift began shortly after the work by Ashbaugh et al. in 1967 when the term 
ARDS was first described as a type of sudden manifestation of lung injury as a result of 
indiscriminate stimuli (Ashbaugh, Bigelow, Petty, & Levine, 1967).  Arguably, Mead et al. are 
credited with the early conceptualization of VILI through the use of theoretical models in an 
attempt to assess elastic mechanical properties of the lung.  The authors concluded that 
“mechanical ventilation, by applying high transpulmonary pressures to heterogeneously 
expanded lungs, could contribute to the development of lung hemorrhage and hyaline 
membranes” (Mead, Takishima, & Leith, 1970, p. 602).  A more formal concept of, so-called, 
VILI has eventually been accepted but only well after the work of both Ashbaugh and Mead et 
al. introduced the notion that PPV could be of detriment under certain conditions.   
Irrespective of the particular terminology used in the past, mechanical ventilation via 
PPV has long been known to cause ALI and contribute to overall morbidity and mortality in 
acute care patients (de Prost et al., 2011).  The application of excessive transpulmonary pressure 
as well as the delivery of above physiologic tidal volumes individually have been shown to cause 
VILI in animal models (Dreyfuss & Saumon, 1998).  Ventilator-associated lung injury might be 
a more appropriate term as it is virtually impossible to prove the ventilator as a single cause of 
ALI ("International Consensus Conferences in Intensive Care Medicine: Ventilator-associated 
Lung Injury in ARDS. This official conference report was cosponsored by the American 
Thoracic Society, The European Society of Intensive Care Medicine, and The Societe de 
Reanimation de Langue Francaise, and was approved by the ATS Board of Directors, July 
1999," 1999); however, VILI remains the most common term used to describe ALI that develops 
during mechanical ventilation.  Although VILI is indistinguishable from other forms of lung 
injury, it is still widely accepted that mechanical ventilation has the potential to worsen acute 
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lung disease (Curley et al., 2016; Parker, Hernandez, & Peevy, 1993).  Specific VILI cannot 
absolutely be proven, but a recent review by Curley et al. reiterated the ever-growing body of 
knowledge surrounding the evidence that PPV causes injury and eludes a cellular response 
(Curley et al., 2016). 
As ventilation strategies and modes of PPV have evolved, there has been little 
improvement in overall incidence of ALI and mortality rates (Erickson et al., 2009; A. Esteban et 
al., 2013).  The current fourth generation mechanical ventilators allow for more autonomy in 
delivering positive pressure breaths, but this increased capability requires more decision-making 
when implementing a modern mode of PPV.  PPV poses significant risk, regardless of the mode 
(Rittayamai et al., 2015), and clinicians must remain astute when seeking not only to prevent but 
also to treat VILI and ALI.  
Although microprocessor-controlled, later-model ventilators are more sensitive to a 
patient’s biofeedback, improperly implemented modes of PPV can have deleterious effects in the 
lung (de Prost et al., 2011).  Clinicians are able to apply and limit specific ventilation pressure 
and maintain relative control of many aspects of the breath cycle (Kacmarek, 2011), yet there are 
numerous variables to consider in order to ventilate safely an array of patient populations.  In 
summary, VILI is a consequence of several mechanisms that include: 1) barotrauma, resulting 
from excessive pressures; 2) volutrauma, resulting from excessive volumes; 3) atelectrauma, 
from cyclic closing and reopening of alveolar units; and 4) biotrauma, resulting from the 
cytokine/inflammatory mediator release as a result of PPV (Dreyfuss & Saumon, 1998). 
APRV 
 Downs and Stock introduced a newer mode of PPV, known as APRV, to the healthcare 
market circa 1987.  Their original study was small (N = 10) and utilized animal models (dogs), 
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comparing APRV with one other traditional mode of PPV.  As a novel approach to applying 
CPAP, the findings suggested that APRV was a viable mode to treat ALI because arterial 
oxygenation improved, and peak airway pressures were maintained at a lower state than the 
traditional mode (J. B. Downs & Stock, 1987).  The next year, the same group conducted the first 
human trial of APRV with similar findings in that patients with ALI were able to be successfully 
ventilated at lower peak airway pressures compared to traditional PPV (Garner et al., 1988).  
Subsequently, a patent was issued to Dr. Downs the same year for his invention of the new PPV 
mode (J.B. Downs, 1988). 
After two landmark studies (J. B. Downs & Stock, 1987; Garner et al., 1988) were 
published, scores of variable types of studies were conducted to evaluate the efficacy of APRV.  
Eventually, APRV was established as a means for implementing a protective lung strategy for 
the non-injured lung as well as a recommended early treatment for ALI or ARDS (Habashi, 
2005; Varpula et al., 2004).  More recently, it has been suggested that early implementation of 
APRV prevents VILI in the normal lung (Emr et al., 2013; F. Facchin & Fan, 2015).  Overall, 
however, there remains a lack of specific recommendation on how best to apply this protective 
ventilation strategy (Jain et al., 2016).  
It is well established that the APRV mode of PPV allows opportunity to mechanically 
ventilate patients, utilizing a protective lung strategy as the mode allows for sustained inflation 
of the lung over a more prolonged period than does traditional IRV (E. G. Daoud et al., 2012), 
resulting in less cyclic opening and closing of lung units (E. G. Daoud et al., 2012; Habashi, 
2005; Jain et al., 2016; Protti et al., 2013).  In addition to being a pressure-targeting breath 
delivery mode, APRV allows one to set extended I-times for application of IRV (Habashi, 2005).  
Unlike traditional IRV, APRV is pressure-targeted breath delivery with sustained pressures for 
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prolonged I-times that allow for maximal recruitment of lung units, avoiding atelectrauma.  
Furthermore, the patient is allowed to breath spontaneously at maximal inflation pressure, so 
ventilator asynchrony is less of an issue than during traditional IRV (E. G. Daoud et al., 2012). 
The APRV mode offers opportunity not only to prevent VILI but also to treat ALI and 
ARDS.  This IRV pressure-targeted mode is a form of CPAP applied beyond the traditional 
timeframe in which patients are usually in control of their preferred I-time.  Under spontaneous 
conditions, the time taken to inspire is almost identical to the time taken to expire.  Similarly, 
during PPV in traditional CPAP mode, patients choose their own I-time, rarely exceeding the 
time of expiration.  Katz and Marks established that CPAP, compared to spontaneous conditions 
while intubated, allowed for a decrease in a patient’s work of breathing (WOB) (Katz & Marks, 
1985).  The understanding of the benefits of CPAP has changed over the years, and APRV mode 
has gained recognition as a more effective PPV mode in the allowance of spontaneous breathing 
(E. G. Daoud et al., 2012; Varpula et al., 2004).   
 When APRV was originally introduced into healthcare, it was touted as a mode of PPV 
that mimicked CPAP; however, unlike CPAP, APRV allows for continuous pressure application 
for a prolonged time period while conserving the patient’s ability to trigger spontaneous efforts.  
The major difference between traditional CPAP and APRV lies in the fact that, in APRV, 
pressure is applied similar to IRV pressure-targeted modes, but only APRV allows patients to 
continue breathing spontaneously at a sustained inflation pressure.  A short release time allows 
for ventilation to be accomplished regardless of a patient’s spontaneous efforts (J. B. Downs & 
Stock, 1987). 
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Relevant Theory 
Stress and Strain 
 It has been established that a conglomeration of events leads to the development of VILI 
(Curley et al., 2016).  Of these events, none can be identified as an individual causative factor.  It 
is, however, the process of cyclic opening and closing and the over distention of alveolar units 
that lead to excessive stress and strain in the lung and contributes to the overall development of 
VILI (Chiumello et al., 2008; Protti et al., 2013; A. S. Slutsky & Ranieri, 2014).  In humans, it is 
difficult to quantify stress and strain; however, several parameters have been suggested as being 
analogous to such.   
A paramount study published in the New England Journal of Medicine, in 2000, 
confirmed that in patients with ALI, ventilation with smaller tidal volumes (6 ml/kg) results in 
better clinical outcomes when compared to ventilation with traditional tidal volumes (12 ml/kg).  
This trial, executed by the “ARDSnet” group, additionally found that extra pulmonary organ 
failure and mortality were decreased in the lower tidal volume group ("Ventilation with Lower 
Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the 
Acute Respiratory Distress Syndrome," 2000).  In 2007, a study by Terragni et al. suggested that 
implementation of lower tidal volumes (6 ml/kg) may not be sufficient to protect from lung 
injury.  The group concluded that simply limiting tidal volume, even at plateau pressures < 30 
cmH2O, may not be sufficient protection for certain patients with large areas of non-aerated lung 
(Terragni et al., 2007).  Other studies have explored the concept of using even lower tidal 
volumes (< 6 ml/kg), indicating that volume-targeted ventilation with tidal volumes lower than 6 
ml/kg might enhance lung protection, ultimately preventing VILI (Bein et al., 2013; Terragni et 
al., 2009). 
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Under a majority of circumstances, pressure-targeted modes of PPV are preferred to 
volume-targeted modes for lung protection (Rittayamai et al., 2015).  And, although lower tidal 
volume ventilation compared to conventional tidal ventilation is associated with better clinical 
outcomes (Neto et al., 2015; Serpa Neto et al., 2012), pressure-targeted ventilation is more 
protective against VILI.  Needem et al. evaluated the use of volume-limited ventilation as 
compared to the use of pressure-limited ventilation in a large prospective cohort, noting that lung 
protective ventilation via pressure-limited modes was associated with a substantial long-term 
survival benefit in patients with ALI (Needham et al., 2012).  In patients with ARDS, Amato et 
al. suggested that driving pressure (DP), comparing tidal volume to respiratory-system 
compliance, may be a more sensitive indicator of risk as opposed to individual tidal volume or 
plateau pressure (Amato et al., 2015).  In 2016, the “LUNG SAFE” study by Laffey, et al. 
concluded that both lower plateau and lower driving pressures are associated with improved 
survival in ARDS (Laffey et al., 2016).  The overwhelming concept remains that “VILI 
originates from the interaction between the mechanical power transferred to the ventilable lung 
parenchyma and the anatomo-pathological characteristics of the latter” (Gattinoni et al., 2016, p. 
1574).      
Time Constants 
 In 1955, a well-known joint study between the John Hopkins University School of 
Medicine and Harvard Department of Physiology explored the concept of varying individual 
lung unit compliance, finding this variance is attributed to both volume-elastic and flow-resistive 
properties (Otis et al., 1956).  The group’s findings led to the concept of what would eventually 
be understood as the pulmonary time constant.  As a product of both lung compliance and overall 
system resistance, a time constant is the time required to passively inflate and deflate each lung 
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unit.  Ideally, under normal conditions, 95% of alveoli will be inflated within three time 
constants (0.25 seconds).  However, with lung disease, irrespective of cause, either or both lung 
compliance and airways resistance is often distorted so that filling time for each individual unit 
can be extremely variable (Kacmarek, Stoller, et al., 2016).   
 In certain cases, longer I-times may be required to satisfy one time constant. If I-time is 
inadequate, filling volume remains insufficient, and alveolar ventilation is decreased.  
Furthermore, inadequate filling contributes to the development of widespread atelectasis, 
contributing to more stress and strain in the lung leading to VILI (A. S. Slutsky & Ranieri, 
2014).  The use of longer I-times, beyond customary initial setting for traditional modes of PPV, 
may assure that atelectrauma from under inflation during inspiration is avoided altogether.   
Current Recommendations of APRV Use  
 To date, studies comparing APRV to conventional PPV have yet to demonstrate any 
significant difference in mortality outcomes (Gonzalez et al., 2010; Maxwell et al., 2010; 
Varpula et al., 2004).  Even though the oxygenation benefit of APRV use has been well 
established (E. G. Daoud et al., 2012), there remains an overall lack of consensus concerning 
when to implement this mode of PPV.  The additional challenge remains as to how one should 
manage this non-conventional mode, given the current lack of recommendations.   
 Two of the more common published management strategies of APRV simply include 
generic recommendations for setting the four primary variables of: 1) lung inflation pressure (P 
high), 2) lung inflation time (T high), 3) lung deflation pressure (P low), and 4) lung deflation 
time (T low).  The recommendations of both Habashi and Modrykamien et al. suggest that it is 
best to target I-times of at least 4 seconds with a strategy of matching pre-APRV, conventional 
ventilator plateau pressure as a starting point for P high.  Both published strategies suggested 
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setting T low to target inducement of auto PEEP with an initial P low setting of 0 cmH2O  
(Habashi, 2005; Modrykamien, Chatburn, & Ashton, 2011).  To date, there is still no single 
APRV recommendation widely accepted in respiratory care.  Furthermore, over the last 30 years 
of APRV use, studies have rarely evaluated similar settings in order to assess the efficacy of a 
single APRV strategy (Jain et al., 2016). 
Summary of Literature 
  There is little published data on how exactly to implement and apply certain ventilator 
modes.  Specifically, there seems to be an overall knowledge gap in how best to manage newer 
modes of PPV after their implementation.  Both the physician and RT remain the primary 
decision-makers in the process of both initiating and managing PPV.  After the initial decision of 
choosing the proper mode, the clinician must decide how best to manipulate and maintain PPV in 
a dynamic environment, and few published recommendations exist outside of generic 
suggestions.   
 Lung protective strategies during PPV have been associated with a substantial long term 
survival benefit for patients with ALI (Needham et al., 2012), and APRV offers a means to 
achieve high-level lung protection (Jain et al., 2016).  Although no specific recommendations 
have necessarily been widely adopted, APRV is a mode well-known to offer a means to achieve 
better oxygenation and produce less stress and strain on lung tissue (E. G. Daoud et al., 2012; 
Emr et al., 2013; F. Facchin & Fan, 2015).  Two of the more commonly recommended published 
strategies (Habashi, 2005; Modrykamien et al., 2011) are based on animal studies and theoretical 
considerations and do not address whether a specific I-time is preferred to another. More studies 
are indicated to identify the best means in which to apply the APRV mode.  It remains unknown 
	 28	
whether it is best to target higher I-times with lower plateau pressures or whether shorter I-times 
with higher plateau pressures would be more favorable to the prevention and treatment of ALI.   
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Chapter 3: Methodology 
Introduction to Chapter 3 
  There are many modes of PPV, and each allows various options of implementation and 
management (Metnitz et al., 2009).  Of the choices in PPV modes, pressure-targeted modes have 
been shown to be more lung protective compared to volume-targeted modes (de Prost et al., 
2011; Lachmann, 1992; Rittayamai et al., 2015), and further developments in ventilator 
technology have contributed to favoring IRV as a preferred technique to achieve lung protection, 
while enhancing oxygenation (Burchardi, 1996; Lachmann, 1992; Protti et al., 2013).  APRV 
mode, also known as BiventÒ or BiLevelÒ, (Chopra, Vardhan, & Chopra, 2014) allows the 
employment of a protective lung strategy similar to typical pressure-targeted IRV.  However, 
APRV mode allows for sustained inflation of the lung over a more prolonged period than does 
traditional IRV (E. G. Daoud et al., 2012), resulting in less cyclic opening and closing of lung 
units (E. G. Daoud et al., 2012; Habashi, 2005; Protti et al., 2013).   
 No definitive data exists concerning how APRV should be applied in order to prevent 
VILI compared to applying APRV to treat ALI.  This quantitative study evaluated subjects in the 
intensive care environment of an academic medical center who were placed on PPV via APRV.  
The retrospective analysis sought to compare subjects’ responses to longer I-time versus shorter 
I-time settings and to identify which setting for I-time resulted in better clinical outcomes as 
indicated by P/F ratio, OI, OSI, and MSOFA scores.  This chapter will provide a summary of the 
research design and methodology, rationale, threats, strengths and weaknesses of design, 
subjects’ discussion, reliability and validity, overall resources required, data collection and 
analysis procedures, as well as the limitations and delimitations of the study. 
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Pilot Study 
 A pilot study was completed during the NSU Winter Term in 2016 as part of the 
requirement in the HSP 9007: Research Practicum course.  The pilot was of similar format to this 
larger, more detailed dissertation study but provided only limited data.  However, with N = 20, 
the pilot provided insight into the induction of longer I-times with the application of lower 
MAWP during PPV.  The findings suggested that, in APRV, ventilation with longer I-times at 
lower MAWP tended to result in better short-term clinical outcomes as evidenced by 
better/lower OI and OSI. 
 Although the pilot study did not render statistically significant results, it could be 
appreciated that longer I-times resulted in better OI and OSI, in general.  Additionally, the pilot 
provided an experience in order to allow corrections for future studies along the same topic.  In 
conclusion, the pilot study showed promise in revealing that there may be a correlation between 
how APRV is implemented and managed, and it may show the effect on certain short-term 
clinical outcomes.   
The pilot revealed there is opportunity for more studies related to the topic as well as a 
need to study other modes of PPV.  The lower OI and OSI after implementing APRV with longer 
I-times may indicate that a longer I-time approach is more desirable and a safer means in which 
to utilize the APRV mode, overall.  There is an expectation that clinicians would be offered great 
insight into how best to approach the implementation and management of APRV as the topic is 
studied further.  Also, the pilot, as well as this dissertation study, could culminate into a template 
for other studies of any of the various modes of PPV commonly used in modern-day clinical 
practice.  
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Research Design and Methodology 
This quantitative study evaluated adult subjects in an intensive care environment who 
were placed on the APRV mode of PPV at a large academic medical center between October 1, 
2013 and October 1, 2016.  The investigator performed a retrospective analysis of archived EHR 
data in order to evaluate subjects’ responses to various I-times quantified and described per 
short-term clinical outcomes among the diagnostic tests evaluated.  Each patient’s settings on 
APRV and coinciding parameters as well as concomitant clinical diagnostic values included in 
the prior independent variables list (Ch. 1) were acquired in alignment with the specific 
timeframe in which APRV was employed.  The subjects’ ventilator settings as well as other 
ventilator parameters and diagnostic values were evaluated.  As the main independent variable, 
the I-time category (“short” or “long”), was determined based upon a yield from the stepwise 
regression analysis related to the T-high setting as a predictor.  
 The harvesting of archived EHR data allowed specific insight into a patient’s course of 
care, and clinical outcomes centered on the patient being mechanically ventilated in APRV 
mode.  Once subject information was compiled and all raw data accounted for, demographics 
were appraised for central tendency, and I-time was evaluated for normal frequency distribution.  
As the main outcomes of interest, the pre-APRV dosing and post-APRV dosing P/F ratio, OI, 
OSI, and MSOFA scores were also calculated for each patient, representative of validated 
predictors of clinical outcomes  (Dechert et al., 2014; Ferreira et al., 2001; Grissom et al., 2010; 
Rawat et al., 2015; Vincent et al., 1996).   
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Rationale  
The theoretical framework that guided this research is founded in the evidence-based 
medicine model of best clinical practice ("Evidence-based Medicine. A new Approach to 
Teaching the Practice of Medicine," 1992).  A recent survey in Respiratory Care confirmed there 
is limited consensus among practitioners in implementing and managing APRV (Miller, Gentile, 
Davies, & MacIntyre, 2017), and this study sought to establish the ideal means of implementing 
the APRV mode of PPV. 
Study Setting 
 This study was conducted at an academic medical center in the Southern US.  Primarily, 
all raw data extraction was performed electronically on the medical center campus, but a 
majority of data analysis occurred campus wide and off site.  Some of the secondary data 
extraction was performed off-campus but only within the confines of the prior-approved IRB 
protocol.  All study procedures were performed electronically, utilizing the investigator’s 
personal, secured laptop computer with no direct or indirect investigator/subject interaction.  
This retrospective analysis was an extraction of archival data within a large EHR database.    
Subjects 
Sample size  
Although a conservative target was 100 total subjects with a minimal expectation of 60 
based upon the fact that 20 were extracted as part of the pilot study, the purposive sample yielded 
68 total subjects, overall.  All subjects that met inclusion criteria were to be extracted from the 
UH database from within the dates specified (3-year timeframe) and included as part of the 
sample population for this study.  One barrier to identifying all eligible subjects was that the 
investigator depended upon the UH information office to do the comprehensive search and was 
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only given access to subjects that were identified initially.  A power analysis was not performed 
as all subjects meeting inclusion criteria were included, and the study population was a function 
of the original UH report rendering. 
Inclusion and Exclusion Criteria  
 All subjects, 18 years or older, for which APRV PPV was ordered were considered as 
having met inclusion criteria during the initial Information Office search of the archived EHR.  
Thereafter, only subjects identified as having received APRV for a minimum of approximately 8 
hours consecutively were included.  Preferably, subjects had undergone APRV PPV for at least 
12-24 hours consecutively; however, due to low sample size, subjects receiving APRV for at 
least 8 hours consecutively were included to prevent a loss of power during the analysis.  Only 
adult subjects at the academic medical center with documented APRV PPV between October 1, 
2013 and October 1, 2016 were included in the study. 
 Only subjects not receiving APRV for at least 8 hours were excluded initially.  There 
were subjects that received APRV just under the 8 hours that were included after re-evaluation of 
the overall subject number.  After the initial UH report was compiled, subjects that were placed 
on APRV but found without their settings documented were also excluded.  Moreover, any 
patient lacking the information necessary to calculate neither the P/F ratio, OI, OSI or MSOFA 
score were not included.  Instances such as known aspiration, improper intubation, and 
complicated interventions during the ICU stay should be considered exclusion criteria to be 
evaluated on an individual basis.  However, these incidents could not be confirmed through a 
simple EHR retrospective analysis.  Moreover, any patient found with a pre-existing terminal 
condition, such as end-stage renal disease or aggressive forms of cancer, would also potentially 
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need to be excluded but were not necessarily accounted for during this study in consideration of 
the short-term follow up.   
Specific Procedures  
 Institutional Review Board (IRB) approval was sought via the typical protocol of the 
academic medical center as well as through Nova Southeastern University (NSU).  Once IRB 
approval at both institutions was obtained, a data extraction report request was submitted to the 
UH Information Office.  This team performed a comprehensive, retrospective extraction of the 
EHRs for all adult subjects who were admitted to UH in the intensive care environment and who 
received PPV via APRV mode between October 1, 2013 and October 1, 2016.  This retrospective 
search allowed purposive sampling of a population that met inclusion criteria for the study.  
 Based upon all the initially submitted protocol and inclusion criteria, 102 potential 
subjects were identified.  Once the UH EHR data from the initial sample had been compiled in a 
formal report, the complete applicable EHR numbers and all pertinent information were made 
available to the investigator via secured email.  The complete EHR of all subjects was then 
accessible to the investigator within the confines of the approved IRB protocol, and it was noted 
that many initially listed did not meet inclusion criteria of having received APRV for at least 24 
hours.  Shortly after the report was received, the investigator made a decision to separate out any 
subject that was not placed on APRV for at least 8 consecutive hours as this represents a typical 
8-hour working shift in a hospital setting.  Several subjects that received APRV just under the 8 
hours were included after re-evaluating the total subject number.  The overall goal remained 
identifying patients who received APRV for at least an average of 12-24 hours; however, the loss 
of power was also considered in broadening the selection to include those receiving APRV for a 
shorter time frame (at least 8 hours).  The final yield was N = 68.   
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 The UH medical information office had compiled certain data into a Microsoft® Excel 
spreadsheet, creating a specific database of information that highlighted only the selected fields 
requested on the approved IRB protocol for the original 3-year time period.  Requested fields 
that were initially reported with no data were able to be verified and completed by doing manual 
data extraction for each applicable subject.  This tedious process allowed other measures or 
variables, such as onset of APRV and exact ventilator settings, to be verified.   
 A data collection tool (DCT) form (Appendix A) was created to allow the investigator to 
acquire specific information in a usable format directly from the UH report/spreadsheet.  Manual 
data extraction from the EHR was necessary to ensure complete information in the 2-page DCT 
form.  This search was performed for each subject specifically by MRN and required acquiring 
certain information by an evaluation of a flowsheet or other report.  During this process, various 
data items from the original UH report were able to be confirmed to assure accuracy of the bulk 
information originally provided by the UH Information Office.  After all DCT forms were 
completed, an electronic database was created utilizing FileMakerPro software.  The electronic 
database was exactly templated from the original DCT.  The electronic database allowed for all 
DCT forms data to be input into a usable electronic format that could be converted back to a 
Microsoft® Excel spreadsheet that was directly input into Statistical Package for the Social 
Sciences (SPSS) to allow statistical analyses. 
 Once the initial raw data extraction was performed and all possible missing fields were 
accounted for on both the original spreadsheet and DCT forms, the P/F ratio, OI, OSI, and 
MSOFA scores were calculated for each subject’s pre-APRV and post-APRV dosing.  The 
secondary Excel spreadsheet (edited version of the original spreadsheet report) was utilized to 
input the mathematical formulas required to render specific P/F ratio, OI, and OSI for each 
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subject.  In addition, an “if, then” formula was created in Excel in order to calculate pre-APRV 
and post-APRV MSOFA scores for all subjects.  All complete data was then transferred from the 
DCT forms into the electronic database, converted into an Excel spreadsheet, and transferred 
directly into SPSS.  The final rendering included the following for each subject: 
• Name, MRN 
• Age (years), sex, height (inches), weight (pounds) 
• Intensive care unit (ICU) assigned: Medical, Surgical, Neuro, Other 
• Vent mode prior to APRV initiation 
Pre-APRV Settings and Parameters: 
• Initial inhaled fractional concentration of oxygen (FiO2): % 
• Positive End-Expiratory Pressure (PEEP): cmH2O 
• Peak inspiratory pressure (PIP): cmH2O 
• Mean airway pressure (MAWP): cmH2O 
• Oxygen saturation (SpO2): % 
Initial APRV Settings and Parameters and Post-APRV Dosing Settings and Parameters: 
• I:E ratio 
• FiO2 (%) 
• T high (sec) 
• T low (sec) 
• Respiratory rate (RR) spontaneous: breaths per minute (bpm) 
• RR total: bpm 
• Tidal volume (Vt) exhaled: milliliters (ml) 
• VT spontaneous: ml 
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• P high (cmH2O) 
• P low (cmH2O) 
• PIP (cmH2O) 
• MAWP (cmH2O) 
• Minute ventilation/volume (Ve) 
• PaO2 (mmHg) 
• SpO2 (%) 
 In order to acquire the MSOFA scores at APRV initiation as well as post-APRV dosing, 
the following additional parameters were acquired:  
• Serum bilirubin (mg/dl) 
• Mean arterial blood pressure (mmHg) 
• Confirmation of use and dose of vasopressor medication 
• Glasgow coma scale (GCS) 
• Serum creatinine (mg/dl) 
 A sub-score was assigned to each subject based on mean arterial blood pressure and 
serum creatinine score, templated from the original MSOFA table by Grissom et al. (Grissom et 
al., 2010).  Thereafter, a pre-APRV initiation and post-APRV dosing P/F ratio, OI, OSI, and 
MSOFA score were calculated for each subject.  The serum bilirubin was used from the original 
SOFA metric and scored accordingly to replace the jaundice and icterus account on the MSOFA 
version.  Nevertheless, a MSOFA score was calculated for each subject in order to appreciate 
any significant pre-APRV and post-APRV change.   
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Statistical Analyses 
  The overall sample demographics data were appraised, and specific metrics were 
calculated by descriptive statistics for age, sex, race, height, weight, and body mass index (BMI).  
Additionally, the primary independent variable, initial I-time setting, was initially appraised for 
normal distribution.  Pertinent clinical data was evaluated and reported as a conglomerate.  The 
change scores for the outcomes of interest (dependent variables) were also calculated to identify 
any statically significant result.  Correlation matrixes were created to evaluate whether any 
relationship existed among the categorical and continuous variables.  A bivariate analysis was 
performed for all categorical variables.  An additional correlational matrix was created linking 
predictor variables to change in dependent variable scores, both pre-APRV and post-APRV.  A 
bivariate analysis of categorical variables and change scores was performed.  A multiple 
regression analysis was conducted to identify significant predictors for any of the four dependent 
variables: P/F ratio, OI, OSI, and MSOFA scores.  
 Once pertinent data was accounted for, specific metrics regarding the entire purposive 
sample were calculated, as reported.  The investigator conducted data analysis via SPSS version 
23 and 24 by descriptive and inferential statistics, as applicable.  A p < .05 was considered 
statistically significant; however, each perceived clinically significant variable was reported as 
such.  A stepwise regression analysis was performed to identify any bivariate between outcomes 
and predictors.  A p-value < 0.2 to start was considered statistically significant for all covariates.  
For each outcome variable, the difference between the two groups was considered clinically 
relevant based on published research among the topic as well as expert opinion.  The difference 
was considered statistically significant only if the differences between the two groups were at p < 
.05.  The study sought to evaluate whether there is an I-time associated with ideal clinical 
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outcomes; however, certain covariates should be accounted for and individually ruled out as 
having significant influence on a clinical outcome separate from the I-time on a case-by-case 
basis. 
Instruments and Measures 
 No special instruments were required for this study outside of what would be customary 
for a retrospective analysis of archived EHR data.  A laptop was used to receive, store, and 
process study data.  There were various undisclosed computer programs used during the UH 
initial report compilation process by the Information Office, assumed to be a part of the standard 
data extraction and reporting approach.  An institution-assigned, personal laptop computer was 
utilized as well as various software to include Microsoft Office (Word and Excel) as well as 
SPSS, version 23 and 24 for all statistical analyses.  All measures were reported as originally 
rendered from the extraction process via EHR.  No parameters or values were altered beyond the 
literal, original iteration.   
 The P/F ratio, OI, OSI, and MSOFA scores were all calculated utilizing original versions 
of the required variables.  The applicable equations are listed in the later subtitled “Metrics” 
section. Statistical measures were performed utilizing SPSS, version 23 or 24, and reported as 
originally output.   
Reliability and Validity 
 There are certain assumptions that an EHR contains both reliable and valid information. 
A review by Chan, Fowles, and Weiner (2010) evaluated reliability and validity of extracting and 
abstracting from EHR data.  The group appraised 35 prior studies of EHR data quality and found 
that data reliability was questionable for, mainly, the problem and medication lists.  Their study 
revealed an overall variance among institutions’ practice of documentation and data extraction 
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methods, and it was concluded that overall EHR data quality varies among institutions (Chan et 
al., 2010).   
In this study, the EHR data was taken at face validity, as certain archived information 
would have been auto-generated.  Other parameters were entered into the EHR by a credentialed 
clinician; therefore, a potential for occasional error did exist.  The secondary data extracted from 
archived EHRs was not manipulated and was recorded as it appeared in the original EHR 
annotation.  For this study, the EHR was considered a secondary source, as the patient’s real-
time diagnostic monitors and support devices were considered the primary source.  Other 
information, such as yielded by some equipment with direct communication with EHR, will have 
been auto-generated directly from the primary source; however, all EHR data was considered 
secondary.  
 A majority of what was extracted from the EHR was numerical.  In order to acquire the 
patient’s primary diagnosis, as well as to confirm the necessary metrics, the investigator combed 
through various electronic flowsheets and archived spreadsheets, or similar documentation, only 
as applicable to the extraction criteria as prior annotated.  All raw data were initially transcribed 
from the UH-provided report/spreadsheet onto a DCT form (Appendix A) created specifically 
based on the original protocol.  Additional missing data was copied verbatim from the EHR, and 
once the DCT forms were complete, they were transcribed into a tailored electronic database that 
allowed conversion back to an Excel spreadsheet for the purpose of transmission into SPSS.  
 A systematic approach to extracting the EHR archived data was maintained during the 
course of study.  In order to avoid potential transcription error, the investigator systematically 
extracted all initial missing data by recording directly from the EHR and was the only 
acquisitioner thereof.  Unfortunately, there may be confounding variables such as comorbidities, 
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whether confirmed or not, and other unreported entities that may affect clinical outcomes 
unrelated to the original exposure of interest (I-time).  This was not necessarily confirmed in this 
study.  
 All surrogates used as predictors of short-term clinical outcomes were based upon well-
published, validated instruments and were calculated as represented in the literature (Dechert et 
al., 2014; Ferreira et al., 2001; Grissom et al., 2010; Rawat et al., 2015; Vincent et al., 1996).  
The validity of the raw data, initially extracted by the UH team, is assumed and based solely 
upon the fact that the established academic medical center regularly produces retrospective 
analyses and is accustomed to such requests.  Moreover, there were several steps integrated in 
order to confirm, firsthand, the validity of the report data.  To note, the investigator revisited 
each subject’s EHR a minimum of two times, confirming both the date and time of APRV 
initiation as well as the manually documented PPV settings and parameters for each subject.   
Strengths and Weaknesses of Design 
Strengths 
 The major strength of this retrospective study design lies in the fact that large amounts of 
archived EHR data were accessible and assumed to be accurate as part of the legal medical 
record.  The utilization of archived data allowed the investigator access to the information via 
MRN search and allowed several avenues to confirm the accuracy of the originally submitted 
UH report.  The health information of subjects could easily be secured as only the MRN would 
be able to identify study subjects, and this MRN number was kept secure at all times on the DCT 
forms kept in the investigator’s locked office or all electronic study files stored on the 
investigator’s password-protected computer. 
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 Because the dissertation committee included a variety of experts (Respiratory Therapist, 
Pulmonologist, and Psychometrician/Statistician), the mentoring and steering helped maintain a 
high level of integrity of study design and implementation.  Furthermore, the study design was 
modeled after the structure of a typical retrospective analysis of ICU patients receiving PPV. 
Weaknesses 
 The most notable weakness was the susceptibility of uncorrected confounding or bias.  
Data collection errors were possible as can occur in any study, whether prospective or 
retrospective.  An additional primary weakness of this retrospective study design lies in the fact 
that the archived EHR data had been mostly entered into the system manually, at some point, by 
a variety of healthcare providers.  In a typical EHR, one can assume that there is some degree of 
margin for error, although conclusions about EHR data quality, in general, have yet to be clearly 
presented in the literature (Chan et al., 2010).  Over a 24-hour period, however, it should be 
highly unlikely that multiple clinicians are entering in ventilator settings with error, and at this 
particular academic medical center, a majority of lab results are auto-generated into the EHR 
once results are attained.    
 Because EHR had only been implemented in October of 2013, there was a limited data 
set given the design of a retrospective analysis of only archived EHR data.  Additionally, even 
though the investigator assumed, based on firsthand experience, that a large number of potential 
subjects would be identified having received APRV for at least 24 hours, only 68 were included 
in this study once inclusion criteria were applied.  The small sample size decreased the power of 
the study, overall, but was a function of this study, being a retrospective investigation of a non-
standardized approach to APRV at a single academic medical center.   
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Threats 
 The most significant threat to this retrospective analysis of archived EHR data was the 
low purposive sample population size.  Upon completion of the pilot project (See “Pilot Study 
Summary” section), it was noted that it should be necessary to expand the timeline in which 
EHRs were evaluated from 1 year to 3 years.  Furthermore, a strategic planning meeting was 
held with the Chief Information Officer (CIO) and Lead IT data extractor prior to the 
implementation of this study.  Both the CIO and Lead IT data extractor were informed of the 
study goals and creative means in which subjects meeting inclusion criteria could be potentially 
identified and successfully added to a raw data report.  Nevertheless, only patients that had EHR 
available (established at UH, October, 2013) were considered, given the timeline and procedures 
of this study.   
 The timely documentation of PPV settings could be questionable, dependent upon the 
scenario and when the documentation was performed as well as being dependent upon the 
particular documenting clinician and how detailed their EHR account.  As the EHR PPV data 
will primarily yield what was manually entered, the investigator must make the assumption that 
the information found in the EHR was entered with accuracy and by only those whom possess 
the privilege to do so with the applicable credentials and password-protected access.   
Reflexivity 
 Arguably, inherent bias exists for any investigator.  As an RT and bedside clinician that 
often manages PPV, there is a degree of preference toward certain modes and particular care 
practices.  However, in this study, only the data acquired was evaluated as the investigator had no 
direct contact with subjects or providers.  Likewise, there was no direct involvement with the 
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process of ordering or managing any of the subjects on PPV, neither was there any influence on 
subject selection as inclusion criteria were pre-determined as originally outlined.  
Resource Requirement 
This study required a continued partnership between UH Shreveport, the Louisiana State 
University (LSU)-affiliated academic hospital, and LSU Health Sciences Center (HSC) 
Shreveport School of Allied Health.  UH granted the investigator permission to access particular 
archived EHRs as an extracted retrospective data set shortly after IRB approval.  The LSUHSC 
Shreveport IRB was involved with the receiving and monitoring of all electronic study proposal 
documents as well as with the decision for approval of the drafted protocol.  Both the UH 
Medical Information office as well as the UH IT support staff were involved with the process of 
initial data extraction.   
The LSUHSC Shreveport medical library as well as the NSU library resources were 
utilized for the literature review, and both were further utilized for research of topics related to 
this study.  A majority of all data collection, archive, and analyses was conducted electronically 
by the investigator, utilizing a secured, password-protected laptop computer.  However, several 
individuals assisted as mentors during study execution to include the following Dissertation 
Committee members: Dr. Guy Nehrenz (Chair), Dr. Robert Walter (Clinical Expert), and Dr. 
Patrick Hardigan (Statistical Expert).  The investigator was allotted research time as part of the 
expectation for all unclassified faculty at the LSUHSC Shreveport School of Allied Health 
Professions.  No additional funding was necessary to support this effort.   
Timeline 
This study began immediately after: 1) approval of the initial research proposal (Chapters 
1, 2, and 3) by the Dissertation Committee, 2) NSU IRB approval, and 3) LSUHSC Shreveport 
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IRB approval.  Once initial NSU IRB and LSU IRB approval was obtained, the study remained 
under Center-level status.  It should be noted that, as a result of the pilot study, the original LSU 
IRB protocol remained with expedited approval status until 2018.  Tentatively, the primary raw 
data extraction process was completed on August 11, 2017 with final database completion 
shortly after secondary data was finalized on August 22, 2017.  Preliminary data analysis was 
performed immediately thereafter with continued evaluation of all data ongoing until just prior to 
the initial draft of the Formal Dissertation Report (10.10.17).  
 As a pilot study had already been completed and the data analysis revealed a potentially 
clinically but non-statistically significant result, the investigator efficiently proceeded seeking to 
build further upon the original pilot concept.  The pilot was also used as a general template in 
which to design this particular study.  Overall, the study idea began in late 2016, culminating to 
official implementation immediately after IRB approval by both NSU and LSUHSC Shreveport.  
Ethical Considerations and Review 
 This study required the approval of both the NSU IRB and LSUHSC Shreveport IRB.  
Additionally, because of the long-existing partnership with UH Hospital, it was necessary that 
certain UH officials provided services in order for this study to be carried out.  All patient data 
were kept secure in order to assure study subject privacy and maintain compliance with the 
Health Insurance Portability and Accountability Act.  Additionally, this assurance of security 
allowed the investigator to uphold the fundamental ethical principle of nonmaleficence. 
 The LSUHSC Shreveport IRB committee, along with all applicable personnel and 
offices, provided preliminary review, approval, surveillance, and auditing of all study procedures 
to assure human protection of all the research subjects to be included.  Additionally, the 
Dissertation Chair and Committee was charged with advising and guiding the investigator 
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(Doctoral Candidate) during the process of proposal drafting and study implementation.  
Informed consents were waived, and there was no intervention or subject interaction with the 
investigator.  All study data were treated with utmost respect, and no patient identifiers were 
released to any entity nor were directly referenced in any of the submitted materials. 
Funding 
 No additional funding was necessary to support this effort.  Please refer to the “Resource 
Requirement” section for more information. 
Management of Data  
 In summary, the investigator performed a retrospective analysis of archived EHR data.  
UH Shreveport, the LSU-affiliated academic hospital, granted the investigator permission to 
access particular archived EHRs as an extracted retrospective data set after the IRB protocol was 
approved.  The harvesting of the archived EHR data was initially performed by the UH IT 
department extraction team through the UH Information Office, rendering a raw data spreadsheet 
with accompanying medical record (MR) numbers and creating a specific database of 
information that highlighted only the selected fields requested on the approved IRB protocol.  
The EHR data included original patient data from the study time period: October 1, 2013 and 
October 1, 2016.   
 This formal report, with complete applicable EHR numbers, was made available to the 
investigator via secured email.  At this juncture, the complete EHR of all subjects was then 
accessible to the investigator within the confines of the approved IRB protocol and allowed the 
investigator to perform additional data extraction for any missing fields.  The health information 
of subjects remained secured as only the MRN would be able to identify study subjects, and this 
MRN number was kept in an electronic spreadsheet of which only the investigator had password-
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protected access on an institution-assigned personal lap top computer stored in the investigator’s 
locked office. 
 A DCT form (Appendix A) was created in order to highlight all variables to be studied.  
After a final version of the tool was utilized to compile all raw data into a more organized format 
in which to study variables of interest, an electronic database was created utilizing Microsoft 
FileMakerPro.  This database replicated all fields of the DCT, allowing direct export into a new 
spreadsheet that would ultimately feed data into SPSS. 
 The secondary data extracted from archived EHRs was not manipulated, recorded as it 
appeared in the original EHR annotation.  A majority of what was extracted from the EHR was 
numerical.  In order to acquire necessary metrics, however, the investigator combed through 
various flowsheets and annotations within the EHR, or similar documentation, to fill in any 
missing fields first into the DCT, then transfer into the electronic database.  Once all available 
preliminary data had been entered into the electronic database, all missing fields were accounted 
for by manually combining through the EHR, once again, to identify available potential 
additional data.  Certain missing fields were filled in with the best available data to coincide with 
study variables as best as possible (See “Reliability and Validity” section, under “Special 
Considerations” subheading).   
 Upon study conclusion and after Dissertation Formal Report approval by the committee, 
all electronic data will be stored electronically on the investigator’s password-protected lap top, 
and all DCT forms will remain filed in the investigator’s secured office, according to IRB 
protocol for a period of up to 3 years.  Thereafter, all hard copies of data (DCT forms) will be 
shredded and all electronic study files deleted.   
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Data Analyses 
Safeguards 
 The NSU and LSU IRB-approved protocol was implemented for this study via the 
methodology as outlined in this Chapter (Ch. 3).  Initial data was extracted directly from UH 
EHR archives by the UH Information Office and integrated into a formal report by the IT 
Department, which was made available to the investigator.  Moreover, the investigator explored 
additional archival data within the confines of the IRB-approved protocol, seeking to assure that 
the methodology implementation was consistent with the purpose of the research. Thereafter, 
exact values from the EHR were recorded manually onto a DCT form (Appendix A).  Once 
additional raw data had been collected manually, all data were transcribed from the DCT form 
into an electronic database.  The database was exactly templated from the DCT forms to 
represent pre-APRV initiation parameters and diagnostic values as well as those same values and 
parameters an average of 8-24 hours after APRV mode was implemented.  The database was 
converted to a Microsoft® Excel spreadsheet and, subsequently, into SPSS to allow data 
analysis. 
 During the initial data analysis, the investigator consulted the Dissertation Committee 
statistical expert for steering and thereafter received support in proceeding with the more 
sophisticated statistical processing.  After initial statistical analyses were complete, consulting 
services were sought for assistance with regression analysis and the interpretation thereof.  Only 
what was originally rendered from the compilation of all raw data was input into the SPSS 
software as data fields.  All data analyses, thereafter, were performed via SPSS as a function of 
the original data set.   
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Metrics 
 As this quantitative study employed a retrospective analysis of archived EHR data, the 
investigator sought to appreciate short-term clinical outcomes by evaluating the changes in the 
P/F ratio, OI, OSI, and MSOFA scores between onset of APRV use and cessation after at least 8 
hours of continual use.  Initially, overall sample population demographics were evaluated in 
order to appraise the characteristics of all subjects.  Additionally, an I-time distribution plot was 
created in order to preliminarily evaluate for non-normality of the main independent variable 
(exposure of interest) of study.  All dependent variables were calculated for subjects both prior 
and after having received APRV.  Change in dependent variables was derived by subtracting 
post-APRV P/F ratio, OI, OSI, and MSOFA from pre-APRV P/F ratio, OI, OSI, and MSOFA.   
The goal was to test the original hypothesis that, overall, in APRV mode, the use of a 
longer I-time results in ideal mean airway pressure, less pulmonary stress and strain due to less 
cyclic opening and closing of the lung, and, therefore, overall better clinical outcomes as 
evidenced by better P/F ratio, OI, OSI, and MSOFA scores when compared to the use of shorter 
I-times in a similar patient population.  Multiple regression analysis was conducted to identify 
significant predictors for any of the four dependent variables of P/F ratio, OI, OSI, 
and MSOFA scores.  Different regression models were created for each of the dependent 
variables.  Also, different multiple regression analyses were conducted for pre-APRV and post-
APRV data.  A level of significance of 0.05 was used in the multiple regression analysis.  An 
independent variable was considered a significant predictor of the dependent variable if the p-
value was less than or equal to the level of significance value. 
 In alignment with seeking to answer the original research question “Do patients 
ventilated with longer I-times, in APRV mode, have better short-term clinical outcomes 
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compared to patients ventilated in the same mode with shorter I-times?”, the following 
parameters and diagnostic values were acquired directly from each subject’s EHR as a means of 
eventually assessing the main outcomes of interest: FiO2, PaO2, MAWP, and SpO2.  A standard 
equation was used in order to input these values for calculating OI as follows: (FiO2 x MAWP) / 
PaO2 x 100 (Dechert et al., 2014).  Due to the intermittent unavailability of a PaO2 during the 
study subjects’ clinical care, pulsatile oxygen saturation (SpO2) was used to replace the PaO2.  
This replacement allowed the calculation of a modified OI (OSI) as a surrogate for the more 
traditional OI via an equation as follows: (FiO2 x MAWP/SpO2 x 100) (Rawat et al., 2015).  
Additionally, the following was acquired in order to allow the calculation of each patient’s initial 
MSOFA score: SpO2, FiO2, presence of documented jaundice or bilirubin level, mean arterial 
pressure with confirmation of the presence or absence of pressor treatment (eg. Dopamine and 
Dobutamine), Glasgow coma scale score, and serum creatinine.  The MSOFA score was 
calculated based on the original presented table by Grissom et al. (2010) in order to derive a 0 to 
4 total number (Grissom et al., 2010).  The serum bilirubin was used from the original SOFA 
metric to replace the jaundice and icterus account on the MSOFA version, but this did not affect 
score calculation as the original alignment between MSOFA and original SOFA scoring was 
maintained.  BMI was calculated for each subject and evaluated accordingly based on the 
traditional equation: (mass(kg) / height2(m)) x 703 ("Reprint: 2013 AHA/ACC/TOS Guideline 
for the Management of Overweight and Obesity in Adults," 2013). 
           The P/F ratio, OI, OSI, and MSOFA score calculated for each subject represents a short-
term outcome metric, as each in clinical practice, represent an established, validated gauge of 
patient prognosis (Dechert et al., 2014; Ferreira et al., 2001; Grissom et al., 2010; Rawat et al., 
2015).  The P/F ratio, introduced in 1974 (Horovitz, Carrico, & Shires, 1974), has been studied 
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extensively and found as an accurate predictor of mortality (Cooke et al., 2008).  As P/F ratio 
decreases, predicted mortality increases.  The OI during the first 4 days of PPV is well-known to 
correlate with a 28-day survival and mortality outcome.  As OI increases, survival decreases, and 
predicted mortality increases (Dechert et al., 2014).  As with OI, the OSI is also inversely related 
to mortality; when either OI or OSI increases, predicted mortality increases (Rawat et al., 2015).  
As with OI and OSI, the SOFA and MSOFA scores are highly predictive of clinical outcomes 
associated with mortality in that a higher MSOFA score indicates an increase in mortality risk 
(Ferreira et al., 2001; Grissom et al., 2010).  
 Each calculation for the dependent variables was performed on an Excel spreadsheet by 
inputting the applicable formula for each subject, utilizing parameters prior to APRV initiation 
and post-APRV dosing.  An “if, then” formula was created in Excel in order to calculate pre-
APRV and post-APRV MSOFA scores for all subjects.  All univariate statistics for categorical 
variables are reported as frequencies with proportions.  For continuous variables, the number, 
mean, and standard deviation were reported.  Where relevant, the minimum and maximum due 
are included due to the number of subjects and relatively non-normal distribution of the data 
(Lang, 2006).  
 Subject demographics and pertinent clinical data were calculated to represent the pre-
APRV and post-APRV period and to highlight initial APRV parameters.  The change in scores 
for all dependent variables were calculated, and correlations for associate between continuous 
measures were also performed.  Moreover, a bivariate analysis was performed for all categorical 
variables, and an additional correlational matrix was created, linking predictor variables to 
change in dependent variable scores, both pre-APRV and post-APRV.  A final bivariate analysis 
of categorical variables and change scores was performed.  The main independent variable, I-
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time (T high) was evaluated, along with other continuous and categorical variables by multiple 
regression analysis to identify significant predictors for any of the dependent variables: P/F ratio, 
OI, OSI, and MSOFA.  Any p-value < .05 was considered statistically significant; however, 
some associations are reported at p > .05, as calculated. 
Special Considerations  
 As all data acquired were based on values only accessible within an archived EHR, 
certain special considerations were warranted.  Initial MSOFA scores were calculated within a 
window of less than or equal to 2-hours either just prior to or just after APRV initiation.  
Because the time in which APRV was initiated tended to be random, lab results did not always 
exactly coincide with the particular onset time.  It was found that most labs were acquired every 
12 to 24-hour period depending on physician’s order and the protocol of the particular unit of 
care.  Post-APRV dosing, MSOFA scores were computed based on the required lab inputs in 
order to allow scoring.  Those labs not coincidentally available were sought out and acquired up 
to a period of 48 hours after APRV was terminated.  This was necessary as patients received 
APRV for variable timeframes and had labs acquired equally as random.  Values as close as 
possible to the exact time of APRV cessation were used even if recorded from different panels.   
 The SpO2 and FiO2, as well as MAWP, were readily accessible within a timeframe of 1-
2 hours either pre-APRV or post-APRV dosing, so OI and OSI score calculations were relatively 
unaffected.  For post-APRV dosing individual metrics, the labs coinciding most with the 
timeframe immediately post-APRV were used, but if a particular single lab result was not 
available for that time, the next available missing lab result was utilized (not beyond a period up 
to 48 hours after APRV dosing).  When available, the invasive arterial mean arterial blood 
pressure was utilized as opposed to the non-invasive.  For GCS scores, the attempt was to utilize 
	 53	
the most coincidental record as applicable to pre-APRV and post-APRV timeframe; however, for 
post-APRV dosing, available GCS scores up to 6 hours later were used.  There were subjects that 
received APRV just under the 8 hours which were included after re-evaluation of the initial 
overall subject number.   
Format for Presenting Results 
 This study sought to identify a preferred means in which to apply APRV mode of PPV, 
evaluating I-time as the main independent variable and exposure of interest.  Given the primary 
hypothesis of this study, it is important to present I-time as a viable predictor of short-term 
clinical outcomes for patients receiving APRV within the context of how other parameters are 
directly or indirectly affected by this setting.  Certain other correlations as a quantifiable 
relationship, albeit negative or positive, and also, covariates that affect outcomes, separate of I-
time, are reported as well as any other relationship among variables or any found relation of 
variables to clinical outcomes.  Overall, the study results section includes a statement that 
addresses whether the data analysis offers support to or refutes the original hypothesis. 
 Data was compiled in order to 1) detail all of the general subject characteristics, allowing 
the reader to appraise the study population demographics, 2) provide a summary to overview the 
study clinical data results, and 3) provide the results of the outcomes of interest (dependent 
variables).  Additionally, correlational matrixes are provided for both pre-APRV and post-APRV 
clinical outcomes.  The details of a bivariate analysis are presented in order to appreciate any 
statistically significant association among categorical and continuous variables.  Correlational 
matrixes of predictor variables and change scores both pre-APRV and post-APRV are also 
presented.  The investigator furthermore highlights an additional bivariate analysis of categorical 
variables and change scores, and the multiple regression analysis results are summarized.  
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Generalized study results will be disseminated among the clinical community via local, state, or 
national presentation in addition to being published in a high impact scientific journal.    
Regression Analysis 
 In this exploratory study, multiple regression analysis was conducted to identify 
significant predictors for any of the four dependent variables of P/F ratio, OI, OSI, 
and MSOFA scores.  Different regression models were created for each of the dependent 
variables.  Also, different multiple regression analyses were conducted for pre-APRV and post-
APRV data.  A level of significance of 0.05 was used in the multiple regression analysis.  An 
independent variable was considered a significant predictor of the dependent variable if the p-
value was less than or equal to the level of significance value. 
 As the main outcomes of interest (dependent variables) were the change in P/F ratio, OI, 
OSI, and MSOFA after at least 8 hours on APRV, the initial predictor variables (independent 
variables) included:  1) Age at APRV onset, 2) height, 3) weight, 4) BMI, 5) pre-APRV MAWP, 
6) T high (I-time), 7) T low, 8) P high, 9) P low, and post-APRV MAWP.  Certain other 
variables could be considered clinically relevant but not necessarily statistically significant.  A 
level of significance of 0.05 was used in the multiple regression analysis.  An independent 
variable was considered a significant predictor of the dependent variable if the p-value is less 
than or equal to the level of significance value. 
 The investigator sought to identify correlations of surrogates for short-term outcomes 
(P/F ratio, OI, OSI, and MSOFA) with the predictor variables as prior described in order to 
indicate whether a regression effect was statistically significant.  Moreover, a model summary 
was evaluated via SPSS in order to appreciate particular relationships among the independent 
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and dependent variables.  The investigator sought to identify predictors of best short-term 
clinical outcomes.   
Model Building Strategy 
 Although the SPSS software was utilized for the actual stepwise regression analyses, 
below were the general proposed prediction models to be utilized for the purpose of identifying 
significant relationship between dependent and independent variables:  
• Main model: most feasible outcome of interest:  
o D P/F ratio* = (THigh + PHigh D + initial MSOFA score) 
*P/F ratio was replaced with DOI ratio, DOSI, or DMSOFA although the core model 
remained as described 
• Exploratory model: to include exploratory variables – potential confounders 
o D P/F ratio** = (THigh + PHigh + D MSOFA score) PHigh setting + PLow 
setting + I-time + MAWP 
**P/F ratio was replaced with DOI ratio, DOSI, or DMSOFA although the core model 
would remain as described 
Procedure 
 The investigator began with no predictors within the stepwise model.  A predictor was 
entered, or removed, based on partial F-tests according to t-tests for the slope parameters 
obtained.  The final model was identified when no more predictors could be justifiably entered or 
removed from the stepwise model.  Both the alpha-to-enter (αE) and alpha-to-remove (αR), by 
SPSS default, was kept at 0.2 in order to avoid the elimination of potential impactful predictors.   
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Step 1: Each of the one-predictor models was fitted, that is, regressed y on x1, y on x2, etc.   
Of all predictors, whose t-test P-value is less than αE = 0.2, the first predictor put into the 
stepwise model had the lowest P-value. 
Step 2: The predictor with the lowest P-value (αE < 0.2) was deemed the “best” single 
predictor.  Each two-predictor models were fitted to include the particular “best” single 
predictor - regressing y on x1 and x2, y on x1 and x3, etc.  Each predictor thereafter that 
had a t-test value of αE < 0.2 was included in the stepwise model as a sequential 
predictor.  If a second predictor was identified, then each predictor was entered into the 
stepwise model to evaluate whether the significance of the first predictor was somehow 
affected.  If the t-test P-value for testing β1 = 0 rendered the αR > 0.2, x1 was removed 
from the model. 
Step 3: If both x1 and x2 were to be included in the two-predictor stepwise model after 
aligning with the procedures as prior described, the investigator fit each of the three-
predictor models that include x1 and x2 as predictors, regressing y on x1, x2 and x3, 
regressing x1, x2 and x4, etc.  Of those predictors, whose t-test P-value is αE < 0.20, the 
third predictor put in the stepwise model was the predictor that had the smallest t-test P-
value.  If x3 was deemed the "best" third predictor, then it was entered into the stepwise 
model.  If a third predictor is identified, then each predictor was entered into the stepwise 
model to evaluate whether the significance of the first and second predictor was 
somehow affected.  If the t-test P-value for testing β1 = 0 or β2 = 0, then rendering the αR 
> 0.2, the applicable predictor was removed from the model. 
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Results and Interpretation: Limitations and Delimitations 
This study was primarily limited by the number of subjects (N = 68) whose EHRs were 
made available to the investigator due to the limited number of UH patients who met the 
inclusion criteria.  Furthermore, a main delimitation of this study lies in the fact that the sample 
was drawn from a single academic medical center in the Southern US.  A significant limitation 
of this study was the dependence upon archived EHR information as the source of all data.  
Although the EHR is considered legal documentation, its accuracy is not infallible (Häyrinen, 
Saranto, & Nykänen, 2008). 
 The timeframe in which this study was conducted may have limited the investigator’s 
ability to re-visit the raw data once transferred into the Microsoft® Excel spreadsheet and 
released via email by the UH Information Office.  Additionally, there were several confounding 
variables that may have affected overall outcomes not necessarily attributed to I-time setting or 
PPV.  For example, it was not possible to account for comorbidities or other non-ventilator 
associated acute events in each subject.  A large portion of subjects who require mechanical 
ventilation may be found with significant non-pulmonary disease (Wunsch et al., 2010) that may 
alter the course of care and outcomes.  This alteration would cause a potential skew of certain 
diagnostic parameters and clinical outcomes.   
 Additionally, many subjects had labs available only within 12-24 hours of the time 
APRV was stopped.  This availabilitymay have caused calculated MSOFA scores to be 
somewhat less accurate than if a prospective study was accomplished that could guarantee lab 
values absolutely concurrent with APRV use.   
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Summary   
  In summary, the investigator sought to execute the methodology in a clear, 
comprehensive, and detailed manner in order to assure accurate results and to allow other 
researchers to reproduce the study (Roberts, 2010).  A systematic approach to searching the EHR 
and extracting data was imperative and assured via a step-by-step approach as outlined 
throughout the methodology (Ch. 3).  To ensure the validity and generalizability of the results, 
the methodology was carried out with high fidelity, with every subject DCT being verified at 
least twice.  The study results should offer insight into how better to ventilate patients placed in 
APRV mode.    
 In the next chapter (Ch. 4), the study results are outlined in detail to allow the reader an 
appreciation for the overall summative outcomes.  As there may be clinically relevant results that 
are not necessarily statistically significant and vice versa, one must take this into account as 
findings are presented and appraised.  The expectation is to link study results back to the original 
hypothesis in hopes of answering the general question of: Do patients ventilated with longer I-
times, in APRV mode, have better short-term clinical outcomes compared to patients ventilated 
in the same mode with shorter I-times?  
 The major strength of this study lies in the fact that no other similar study has been 
identified in the literature, so this study is the first of its kind.  Moreover, this study should be of 
great value to the particular academic medical center from which the EHRs were extracted, 
offering insight into best clinical practice.     
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Chapter 4: Results 
Introduction to Chapter 4 
 As stated in Chapter 1, this quantitative study examined the relationship between 
inspiratory time, inflation pressures, and surrogates for short-term clinical outcomes during 
mechanical ventilation via the APRV mode of PPV.  This chapter is organized in terms of how 
the original research question was addressed, how patients were selected as a convenient, 
purposive sample from an academic medical center EHR, and what can be appreciated from the 
findings.  The subject demographic information is listed in Table 1.  The original outcomes of 
interest were the change in subject’s P/F ratio, OI, OSI, and MSOFA scores, and it was 
investigated as to what degree any of the categorical or continuous variables studied effected 
these clinical outcomes.  
 Within the confines of both the LSUHSC Shreveport and NSU-approved IRB protocols, 
a retrospective analysis of archived EHR data was performed to include 68 subjects.  The results 
presented are the product of tedious EHR review and meticulous data analysis of what was 
rendered from the retrospective search.  All data was initially recorded by the UH Information 
Office in original form as extracted from the initial EHR inquiry.  Thereafter, the initial raw data 
was transcribed from the preliminary spreadsheet into a more organized format onto DCT forms 
(Appendix A).  After the electronic database was constructed and filled in with all information 
from the DCT forms, the data was transferred exactly into SPSS.  All statistical analyses were 
performed using version SPSS version 23 or 24, and results are presented in the original format 
as yielded. 
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Data Analysis Results  
 All available data was analyzed for each subject in the sample population (N = 68).  Both 
descriptive and inferential statistics were calculated for all subjects, as reported.  Furthermore, all 
pertinent findings are reported, as applicable to the original research question and hypothesis.  
All data analyses were performed utilizing Microsoft® Excel and SPSS version 23 or 24.   
Subjects  
 The convenient, purposive study sample population was a result from the yield of an 
original inquiry performed by the UH Information Office, producing a total of 68 subjects that 
met inclusion criteria.  The overall study sample population demographics (Table 1) revealed 
subjects tended to be near middle age (N = 68; M = 46.3 years) with a majority of subjects being 
Caucasian (n = 44; 64.7%) and male (n = 49; 72%), most of whom received care in the SICU (n 
= 42; 61.7%).  It was noted that subjects, on average, were classified as clinically obese (M BMI 
= 30.9). 
Table 1: Subject Demographics                       
______________________________________________       
(n = 68)   (𝑥; min-max, SD)      
Age, yr,   46.39 (18-84, 16.77)    
Height, in    68.10 (53-76, 4.87)   
Weight, lbs   204.50 (66-356, 55.30 
BMI    30.90 (13.32-59.23, 7.86)__ 
(n = 67)   n (%) 
Sex, male        49 (72.13) 
Race     
   White   44 (65.67)   
   Black   23 (34.32)  _____ 
(n = 59)   n (%)  
    
MICU    14 (23.72)         
SICU    42 (71.18)      
Neuro ICU   1 (1.69)       
Other    2 (3.38)__________________ 
SICU - Surgical Intensive Care Unit 
MICU - Medical Intensive Care Unit 
Neuro ICU – Neurosurgical Intensive Care Unit 
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Pre-APRV  
 Table 2 provides an overview of clinical data.  Although one subject was missing 
documentation as to which mode of PPV subject was placed prior to being placed on APRV, of 
the overall sample (N = 67), most subjects had been placed in PRVC (n = 30; 44.8%) or PS mode 
(n = 23; 34.3%) prior to APRV initiation with 100% FiO2 being the most prevalent setting for 
pre-APRV FiO2 (23.9%).  Pre-APRV mean airway pressure in subjects was variable (M = 
15.03) but most commonly found at 12-13 cmH2O (n = 13; 19.4%).  Subject’s pre-APRV SpO2 
was also variable (IQR = 6) but found most commonly to be 94-100%.  It was not possible to 
deduce the precipitating event that led to a decision to place a patient on APRV, and no 
consistent pattern could be appreciated for initial settings. 
Table 2: Clinical Data 
________________________________________________ 
Pre-APRV Mode  n (%) 
            
PRVC    30 (44.77) 
PC    8 (11.94) 
PS    23 (34.32) 
Unknown                        6 (8.95)  
 
    n, 𝒙 (SD) 
MAWP    63, 15.03 (5.75) 
FiO2    65, 70.98 (22.08) 
________________________________________________ 
Pre-APRV Initiation: n (𝒙; min-max, SD) 
       
SpO2    67 (93.46; 78.00-100.00, 4.98) 
P/F ratio1    44 (96.39;26.00 – 222.50, 44.09)      
Pre-APRV OI2   43 (27.34; 5.42-88.46, 14.55) 
Pre-APRV OSI3   63 (18.99, 6.73-75.00, 9.67) 
Pre-APRV MSOFA4   58 (8.96, 2.00-17.00, 3.20) 
_________________________________________________  
APRV Initial Parameters: n (𝒙; min-max, SD) 
 
Thigh, sec    65 (6.30; 0.90-11.00, 2.65) 
Tlow, sec    61 (1.21; .40-10.00, 1.41) 
Phigh, cmH2O   65 (24.2; 18.00-35.00, 3.33) 
Plow, cmH2O   68 (3.51; 0.00-15.00, 4.47) 
MAWP, cmH2O  66 (21.87; 4.00-31.00, 4.28) 
_________________________________________________ 
Post-APRV Dosing   n (𝒙; min-max, SD) 
 
Total Time on APRV,hrs 68 (19.27; 6.80-24.96, 5.49) 
 
SpO2    68(93.51; 70.00-100.00, 5.47)      
P/F ratio1    21(147.27; 33.75-300.00, 71.63)      
Post-APRV OI2   21 (19.81; 4.19-56.29, 14.12)  
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Post-APRV OSI3   68 (12.27; 1.68-26.66, 5.75) 
Post-APRV MSOFA4  58 (8.79; 2.00-17.00, 3.16) 
_____________________________________ 1PaO2/FiO2 2Oxygen Index = (FiO2*MAWP)/PaO2*100 
3Oxygen Saturation Index = (FiO2*MAWP)/SpO2*100 
4Modified Sequential Organ Failure Assessment Score 
 
 It was not common to have a PaO2 available that coincided with APRV initiation nor 
even a few hours surrounding the implementation of APRV, thus SpO2 was used as a surrogate 
for this value in order to acquire MSOFA scores at or near onset of APRV.  The available pre-
APRV MSOFA scores (n = 58) revealed a majority of subjects were considered at greater than 
normal risk category (x̅ = 8.9; s = 3.2). 
APRV Dosing 
 There was an initial target of identifying only potential subjects that had been placed on 
APRV for a 24-hour period, but, due to low sample size, it was determined to include all patients 
that had received at least 8 hours of APRV consecutively.  Incidentally, a few were added having 
received APRV for just under the 8-hour total window.  On average, subjects received APRV 
consecutively for 19.27 hours (min-max = 6.80-24.96; SD = 5.49).  Post-APRV SpO2 was 
higher than pre-APRV SpO2, but the difference was not statistically significant.    
 PPV settings among subjects were highly variable, and no particular underlying pattern 
was noted.  The average setting for I-time (T high) was 6.30 seconds with high variability noted 
(0.9 sec to 11.0 secs).  PPV settings for T low, P high, and P low were also highly variable (see 
Table 2). 
Main Outcomes of Interest  
 A paired t-test was performed to compare the change in all scores for the dependent 
variables.  There was noted improvement in P/F ratio, OI, OSI, and MSOFA scores, on average, 
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for all subjects (see Table 3).  There was statistically significant improvement in change scores 
for both P/F ratio (44.28 average increase; p = 0.12) and OSI (6.34 average decrease; p = 0.00). 
Table 3: Outcomes of Interest (Dependent Variables) 
____________________________________________________________ 
∆ Score: Pre-Post APRV  n (𝑥, SD)   p-value 
 
P/F Ratio    18(-44.28, 66.42)  .012  
OI     18(8.77, 20.44)  .086 
OSI     63(6.34, 9.50)   .000 
MSOFA __________________52(.096, 2.45)_____________.778___ 
Paired t-test performed 
 
Correlational Matrixes 
 Tables 4, 5, 6, and 7 provide an overview of all correlational matrixes results.  Although 
the original independent variable (I-time) did not prove to correlate with statistical significance 
with any of the four dependent variables (P/F ratio, OI, OSI, and MSOFA), it is well established 
that I-time has a direct impact upon various parameters during PPV via APRV (E. G. Daoud et 
al., 2012).  The following variables were found to have statistically significant correlation with 
surrogates for pre-APRV clinical outcomes:  
P/F ratio: None 
OI:  Initial MAWP, r(41) = .348, p < .05 
OSI:  Initial P high, r(58) = .294, p < .05;  Initial MAWP, r(61), p < .05 
MSOFA: Initial P low, r(56) = .385, p < .01 
 The following variables were found to have statistically significant correlation with 
surrogates for post-APRV clinical outcomes: 
P/F ratio: BMI, r(19) = .457, p < .05 
OI:  BMI, r(19) = -.478, p < .05;  P low, r(19) = .466, p < .05 
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OSI:  T low, r(61) = -.260, p < .05;  P high, r(63) = .418, p < .01;  MAWP, r(66) =  
  .577, p < .01 
MSOFA: P high, r(53) = .360, p < .01 
 Regarding change scores, the only pre-APRV variable found to have statistically 
significant correlation with a clinical outcome was initial P low with ∆OI: r(16) = -.545, p < .05.  
In reference to change scores, no post-APRV variables were found to have statistically 
significant correlation with clinical outcomes.  However, in consideration of the low sample size, 
APRV duration, P high, and MAWP could be viewed as impactful based on the close proximity 
of each variable to statistical significance in correlation to one of the four clinical outcomes 
evaluated.  
Table 4: Correlation Matrix for Clinical Outcomes: Pre-APRV 
 
      P/F ratio OI OSI MSOFA  
Age Corr.  0.200 -0.168 0.001 0.230 
 Sig.  0.192 0.282 0.991 0.082 
  N  44 43 63 58 
Height Corr.   -0.079 0.172 0.170 0.036 
 Sig.  0.609 0.269 0.183 0.790 
 N  44 43 63 58 
Weight Corr.   0.170 -0.124 0.099 0.210 
 Sig.  0.271 0.427 0.442 0.114 
 N  44 43 63 58 
 BMI Corr.   0.216 -0.209 0.017 0.233 
 Sig.  0.160 0.179 0.894 0.079 
 N  44 43 63 58 
Pre-APRV 
MAWP Corr.   0.012 0.099 0.086 0.045 
 Sig.  0.942 0.549 0.519 0.745 
 N  40 39 59 54 
Initial 
Thigh Corr.   -0.115 0.192 0.062 -0.233 
 Sig.  0.473 0.235 0.639 0.084 
 N  41 40 60 56 
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Initial Tlow Corr.   -0.080 -0.224 0.113 0.178 
 Sig.  0.626 0.176 0.407 0.207 
 N  39 38 56 52 
Initial 
Phigh Corr.   -0.126 0.159 .294* 0.235 
 Sig.  0.425 0.321 0.022 0.084 
 N  42 41 60 55 
Initial Plow Corr.   -0.045 -0.03 0.063 .385** 
 Sig.  0.770 0.848 0.622 0.003 
 N  44 43 63 58 
Initial 
MAWP Corr.   -0.054 .348* .292* 0.154 
 Sig.  0.729 0.022 0.02 0.257 
  N   43 43 63 56 
* Correlation is significant at the 0.05 level     
** Correlation is significant at the 0.01 level     
 
Table 5: Correlation Matrix for Clinical Outcomes: Post-APRV; At Cessation 
	   P/F ratio  OI OSI MSOFA  
Age Corr. 0.047 -0.180 0.040 0.235 
 Sig. 0.838 0.434 0.746 0.075 
 N 21 21 68 58 
Height Corr. -0.344 0.298 0.020 0.087 
 Sig. 0.127 0.189 0.87 0.514 
 N 21 21 68 58 
Weight Corr. 0.283 -0.362 -0.103 0.183 
 Sig. 0.214 0.106 0.404 0.168 
 N 21 21 68 58 
BMI Corr. .457* -.478* -0.088 0.193 
 Sig. 0.037 0.028 0.474 0.148 
 N 21 21 68 58 
APRV 
Duration Corr. -0.296 0.308 -0.027 0.008 
 Sig. 0.193 0.174 0.830 0.950 
 N 21 21 68 58 
Thigh Corr. 0.148 0.147 0.123 -0.167 
 Sig. 0.535 0.535 0.336 0.232 
 N 20 20 63 53 
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Tlow Corr. -0.025 -0.210 -.260* -0.068 
 Sig. 0.918 0.373 0.040 0.630 
 N 20 20 63 53 
Phigh Corr. -0.067 0.090 .418** .360** 
 Sig. 0.773 0.698 0.001 0.007 
 N 21 21 65 55 
Plow Corr. -0.329 .466* 0.128 0.227 
 Sig. 0.146 0.033 0.311 0.095 
 N 21 21 65 55 
MAWP Corr. -0.141 0.336 .577** 0.167 
 Sig. 0.542 0.136 .000 0.209 
  N 21 21 68 58 
* Correlation is significant at the 0.05 level    
** Correlation is significant at the 0.01 level    
 
Table 6: Correlation Matrix of Predictor Variables and Change Scores: Pre-APRV 
  ∆ P/F ratio ∆ OI ∆ OSI ∆ MSOFA 
Age Corr. 0.063 -0.022 -0.062 -0.191 
 Sig.  0.804 0.932 0.628 0.176 
 N 18 18 63 52 
Height Corr. 0.105 0.156 0.139 -0.098 
 Sig.  0.678 0.535 0.278 0.489 
 N 18 18 63 52 
Weight Corr. -0.019 0.078 0.165 -0.103 
 Sig.  0.941 0.758 0.196 0.468 
 N 18 18 63 52 
BMI Corr. -0.064 -0.012 0.084 -0.070 
 Sig.  0.801 0.964 0.515 0.622 
 N 18 18 63 52 
Pre-APRV 
MAWP Corr. -0.397 0.188 -0.050 -0.137 
 Sig.  0.115 0.47 0.709 0.346 
 N 17 17 59 49 
Initial 
Thigh Corr. -0.458 0.281 0.031 0.038 
 Sig.  0.074 0.292 0.817 0.795 
 N 16 16 60 50 
Initial 
Tlow Corr. 0.371 -0.334 0.093 0.087 
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 Sig.  0.158 0.206 0.496 0.561 
 N 16 16 56 47 
Initial 
Phigh Corr. -0.288 0.408 0.142 -0.139 
 Sig.  0.247 0.093 0.280 0.341 
 N 18 18 60 49 
Initial 
Plow Corr. 0.407 -.545* -0.051 0.075 
 Sig.  0.094 0.019 0.692 0.595 
 N 18 18 63 52 
Initial 
MAWP Corr. -0.371 0.338 0.166 -0.020 
 Sig.  0.130 0.170 0.195 0.893 
 N 18 18 63 50 
* Correlation is significant at the 0.05 level  
** Correlation is significant at the 0.01 level  
 
Table 7: Correlation Matrix of Predictor Variables and Change Scores: Post-APRV; At 
Cessation 
  ∆ P/F ratio ∆ OI ∆ OSI ∆ MSOFA 
APRV 
Duration Corr. 0.267 -0.23 -0.214 -0.081 
 Sig.  0.284 0.359 0.092 0.570 
 N 18 18 63 52 
Thigh Corr. -0.256 -0.122 -0.017 0.052 
 Sig.  0.322 0.642 0.901 0.727 
 N 17 17 58 47 
Tlow Corr. 0.137 0.243 0.063 0.079 
 Sig.  0.601 0.346 0.640 0.595 
 N 17 17 58 47 
Phigh Corr. -0.284 0.437 0.024 -0.257 
 Sig.  0.254 0.070 0.852 0.075 
 N 18 18 61 49 
Plow Corr. 0.215 -0.226 0.025 0.100 
 Sig.  0.391 0.368 0.848 0.495 
 N 18 18 61 49 
MAWP Corr. -0.434 0.214 -0.179 -0.149 
 Sig.  0.072 0.393 0.162 0.293 
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 N 18 18 63 52 
* Correlation is significant at the 0.05 level.   
** Correlation is significant at the 0.01 level.  
 
Bivariate Analyses 
 Tables 8 and 9 provide an overview of the bivariate analysis results.  In evaluation of 
categorical variables, no statistically significant relationship was found between categorical 
variables and P/F ratio and OI.  However, the ICU in which subjects were managed while on 
APRV bears statistical significance with post-OSI (p = .022) and both pre-MSOFA (p = .014) 
and post MSOFA (p = .030) showing empirical relation.  Additionally, ICU in which subjects 
were managed was found with statistically significant relation to ∆ P/F ratio (p = .034).  This 
could be considered simple artifact and not clinically meaningful. 
Table 8: Bivariate Analyses 
   Pre-P/F Ratio              Post-P/F Ratio__________________ 
    
   n (𝑥, 𝑆𝐷)  p-value n (𝑥, 𝑆𝐷)  p-value 
     
Sex      .848     .096 
Male   30(95.50, 44.52)   14(126.445, 60.094)  
Female  14(98.30, 44.75)   7(188.928, 79.025)  
 
Race      .706     .343 
White   29(98.22, 44.88)   13(157.64, 84.63) 
Black   15(92.86, 43.84)   8(130.42, 43.12) 
             
ICU      .345     .397 
MICU   10(87.24, 31.72)   5(121.91, 93.29) 
SICU   24(100.56, 46.72)   10(164.67, 69.07) 
     
Pre-APRV Mode:    .163     .997 
PRVC   22(103.810, 53.306)   10(150.311, 77.178)  
PS/CPAP  11(81.879, 33.993)   5(150.091, 105.727) 
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   Pre-OI    Post-OI_______________________ 
    
   n (𝑥, 𝑆𝐷)  p-value n (𝑥, 𝑆𝐷)  p-value 
     
Sex      .522     .102 
Male   29(28.04, 16.28)   14(22.81, 15.70)   
Female  14(25.89, 10.51)   7(13.83, 8.20)  
 
Race      .217     .929   
White   28(25.01, 11.80)   13(20.07, 17.19) 
Black   15(31.68, 18.33)   8(19.51, 7.90)   
             
ICU      .555     .305   
MICU   10(29.12, 10.06)   5(28.65, 21.69) 
SICU   24(26.27, 17.37   10(16.88, 10.89) 
     
Pre-APRV Mode:    .292     .508 
PRVC   21(25.03, 12.97)   10(19.15, 15.11) 
PS/CPAP  11(32.34, 20.06)   5(26.17, 19.67) 
 
        
   Pre-OSI                         Post-OSI______________________ 
    
   n (𝑥, 𝑆𝐷)  p-value n (𝑥, 𝑆𝐷)  p-value 
     
Sex      .198     .983 
Male   45(19.78, 10.80)   49(12.26, 6.18) 
Female  18(17.03, 5.77)   19(12.29, 4.61) 
 
Race      .660     .791 
White   40(19.35, 11.11)   44(12.13, 5.62) 
Black   23(18.36, 6.64)   24(12.53, 6.08) 
             
ICU      .312     .022  
MICU   14(20.74, 6.73)   14(15.59, 5.22) 
SICU   39(18.16, 11.04)   42(11.54, 5.83) 
     
Pre-APRV Mode:    .322     .583 
PRVC   28(17.56, 6.83)   30(11.75, 5.58) 
PS/CPAP  23(20.68, 13.52)   23(12.64, 6.00) 
 
        
   Pre-MSOFA                          Post-MSOFA__________________ 
    
   n (𝑥, 𝑆𝐷)  p-value n (𝑥, 𝑆𝐷)  p-value 
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Sex      .303     .739 
Male   42(9.21, 3.36)    42(8.88, 3.17) 
Female  16(8.31, 2.75)     16(8.56, 3.24) 
 
Race      .441     .777 
White   40(9.20, 3.05)    37(8.70, 3.16) 
Black   18(8.44, 3.55)    21(8.95, 3.23) 
             
ICU      .014     .030 
MICU   12(10.91, 3.11)   13(10.38, 2.66) 
SICU   37(8.13, 2.83)    36(8.27, 3.26) 
     
Pre-APRV Mode:    .625     .390 
PRVC   25(9.32, 3.50)    25(9.20, 3.35) 
PS/CPAP  19(8.78, 3.56)    18(8.27, 3.47) 
 
Table 9: Bivariate Analyses of Categorical and Change Scores 
  ∆ P/F Ratio  ∆ OI   ∆ OSI   ∆ MSOFA 
  p-value  p-value  p-value  p-value 
  n (𝑥, 𝑆𝐷)  n (𝑥, 𝑆𝐷)   n (𝑥, 𝑆𝐷)  n (𝑥, 𝑆𝐷)  
     
Sex  .597   .627   .314   .427 
Male  12(-37.79, 64.70) 12(10.04, 24.91) 45(6.99, 10.37) 38(-0.05, 2.59) 
Female 6(-57.26, 74.09)  6(6.23, 6.64)  18(4.72, 6.85)  14(0.50, 2.02) 
 
Race  .977   .318   .589   .964  
White  11(-44.65, 70.82) 11(4.28, 15.71) 40(6.76, 11.17) 35(0.08, 2.54) 
Black  7(-43.70, 64.35) 7(15.83, 26.02) 23(5.61, 5.65)  17(0.11, 2.31) 
             
ICU  .034   .059   .663   .738 
MICU  4(-1.92, 15.29) 4(-5.73, 10.32) 14(5.15, 7.06)  11(0.18, 1.77) 
SICU  8(-78.28, 81.41) 8(17.46, 27.01) 39(6.27, 10.85) 33(-0.06, 2.73) 
     
Pre-APRV   
Mode:  .207   .493   .365   .210 
PRVC  8(-25.08, 55.05) 8(4.62, 15.05)  28(5.33, 7.46)  22(-0.22, 2.67) 
PS/CPAP 5(-88.19, 89.68) 5(16.76, 34.67) 23(8.03, 12.36) 16(.75, 2.04) 
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Regression Analysis 
Multiple regression analysis was conducted to identify significant predictors for any of the 
four dependent variables of P/F ratio, OI, OSI, and MSOFA scores.  Different regression models 
were created for each of the dependent variables.  Also, different multiple regression analyses 
were conducted for pre-APRV and post-APRV data.  A level of significance of 0.05 was used in 
the multiple regression analysis.  An independent variable was considered a significant predictor 
of the dependent variable if the p-value was less than or equal to the level of significance value. 
          Pre-APRV Results 
For the pre-APRV data, the independent variables included the age, height, weight, BMI, 
Pre-APRV MAWP, T high, T low, P high, P low, and APRV MAWP.  Tables 10 to 13 
summarize the results of the different multiple regression analyses to determine which pre-
APRV scores of the independent variables are significant predictors of the pre-APRV scores of 
P/F ratio, OI, OSI, and MSOFA. 
Table 10 summarizes the results of the multiple regression analysis to determine which are 
significant predictors of pre-APRV P/F ratio.  The regression results showed that the model fit of 
the regression model (F (10, 20) = 1.40, p = 0.25) generated was insignificant indicating that the 
regression model did not have an acceptable model fit.  The r-square value of the regression 
model was 0.41, which indicates a moderate effect size and that the combined effects of all 
independent variables captured 41% of the variance in predicting the pre-APRV P/F ratio.  The 
investigation of the individual impacts showed that only the pre-APRV P low (t (30) = -2.12, p = 
0.05) was a significant predictor of pre-APRV P/F ratio.  This was the only p-value less than the 
level of significance value.  Investigation of the unstandardized beta coefficient value showed 
that pre-APRV P low negatively predicted pre-APRV P/F ratio.  A one score increase in pre-
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APRV P low will result to a 5.27 increase in the pre-APRV P/F ratio.  This means that the higher 
the pre-APRV P low, the lower the pre-APRV P/F ratio. 
 
Table 10: Multiple Regression Results of Predictors of Pre-APRV P/F Ratio  
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
B Std. Error Beta 
1 (Constant) 3.53 503.62   0.01 0.99 
Age -0.04 0.63 -0.01 -0.07 0.95 
Height 1.60 7.65 0.14 0.21 0.84 
Weight -0.79 1.36 -0.87 -0.58 0.57 
BMI 7.70 8.92 1.14 0.86 0.40 
Pre-APRV MAWP 0.11 1.69 0.01 0.07 0.95 
APRV Initial T High -8.82 4.44 -0.50 -1.99 0.06 
APRV Initial T Low 42.53 22.68 0.49 1.88 0.08 
APRV Initial P High -9.88 7.11 -0.54 -1.39 0.18 
APRV Initial P Low -5.27 2.49 -0.45 -2.12   0.05* 
APRV Initial MAWP 8.32 6.95 0.59 1.20 0.25 
Note. F(10, 20) = 1.40, p = 0.25, R Square (R2) = 0.41, n = 30 
a. Dependent Variable: APRV initial P/F ratio 
b. Predictors: (Constant), APRV Initial MAWP, Height, APRV Initial P Low, Age, Pre-
APRV MAWP, BMI, APRV Initial T Low, APRV Initial T High, APRV Initial P High, 
Weight 
*Significant at level of significance of 0.05 
 
Table 11 summarizes the results of the multiple regression analysis to determine which are 
significant predictors of pre-APRV OI.  The regression results showed that the model fit of the 
regression model (F (10, 20) = 1.18, p = 0.36) generated was insignificant indicating that the 
regression model did not have an acceptable model fit.  The r-square value of the regression 
model was 0.41, which indicates a moderate effect size and that the combined effects of all 
independent variables captured 41% of the variance in predicting the pre-APRV OI.  The 
investigation of the individual impacts showed that all independent variables of age (t (30) = 
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0.10, p = 0.92), height (t (30) = 0.59, p = 0.56), weight (t (30) = -0.13, p = 0.90), BMI (t (30) = -
0.18, p = 0.86), Pre-APRV MAWP (t (30) = 0.65, p = 0.52), T high (t (30) = 120, p = 0.25), T 
low (t (30) = -0.99, p = 0.34), P high (t (30) = 1.00, p = 0.33), P low (t (30) = 0.94, p = 0.36), and 
APRV MAWP (t (30) = -0.53, p = 0.60) were not significant predictors of pre-APRV OI.  This 
was because all the p-values were greater than the level of significance value. 
Table 11: Multiple Regression Results of Predictors of Pre-APRV OI 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
B Std. Error Beta 
1 (Constant) -88.93 166.46   -0.53 0.60 
Age 0.02 0.21 0.02 0.10 0.92 
Height 1.49 2.53 0.42 0.59 0.56 
Weight -0.06 0.45 -0.20 -0.13 0.90 
BMI -0.52 2.95 -0.24 -0.18 0.86 
Pre-APRV MAWP 0.36 0.56 0.12 0.65 0.52 
APRV Initial T High 1.76 1.47 0.31 1.20 0.25 
APRV Initial T Low -7.40 7.50 -0.27 -0.99 0.34 
APRV Initial P High 2.34 2.35 0.40 1.00 0.33 
APRV Initial P Low 0.77 0.82 0.21 0.94 0.36 
APRV Initial MAWP -1.22 2.30 -0.27 -0.53 0.60 
Note.  F(10, 20) = 1.18, p = 0.36, R Square (R2) = 0.41, n = 30 
a. Dependent Variable: APRV initial OI 
b. Predictors: (Constant), APRV Initial MAWP, Height, APRV Initial P Low, Age, Pre-
APRV MAP, BMI, APRV Initial T Low, APRV Initial T High, APRV Initial P High, 
Weight 
 
Table 12 summarizes the results of the multiple regression analysis to determine which are 
significant predictors of pre-APRV OSI.  The regression results showed that the model fit of the 
regression model (F (10, 37) = 0.69, p = 0.73) generated was insignificant indicating that the 
regression model did not have an acceptable model fit.  The r-square value of the regression 
model was 0.16, which indicates a low effect size and that the combined effects of all 
independent variables captured 16% of the variance in predicting the pre-APRV OSI.  The 
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investigation of the individual impacts showed that all independent variables of age (t (47) = 
0.08, p = 0.94), height (t (47) = 0.23, p = 0.82), weight (t (47) = 0.17, p = 0.87), BMI (t (47) = -
0.23, p = 0.82), APRV MAP (t (47) = 0.72, p = 0.48), T high (t (47) = 0.87, p = 0.39), T low (t 
(47) = 0.95, p = 0.35), P high (t (47) = 0.25, p = 0.80), P low (t (47) = -0.18, p = 0.86), and 
MAWP (t (47) = 0.19, p = 0.85) were not significant predictors of pre-APRV OSI.  This was 
because all the p-values were greater than the level of significance value. 
Table 12: Multiple Regression Results of Predictors of Pre-APRV OSI 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
B Std. Error Beta 
1 (Constant) -26.10 101.60   -0.26 0.80 
Age 0.01 0.10 0.01 0.08 0.94 
Height 0.35 1.54 0.15 0.23 0.82 
Weight 0.04 0.26 0.24 0.17 0.87 
BMI -0.39 1.73 -0.27 -0.23 0.82 
Pre-APRV MAWP 0.25 0.35 0.13 0.72 0.48 
APRV Initial T High 0.77 0.88 0.20 0.87 0.39 
APRV Initial T Low 2.48 2.61 0.19 0.95 0.35 
APRV Initial P High 0.32 1.24 0.09 0.25 0.80 
APRV Initial P Low -0.08 0.45 -0.03 -0.18 0.86 
APRV Initial MAWP 0.22 1.18 0.08 0.19 0.85 
Note.  F(10, 37) = 0.69, p = 0.73, R Square (R2) = 0.16, n = 47 
a. Dependent Variable: APRV initial OSI 
b. Predictors: (Constant), APRV Initial MAWP, Height, APRV Initial P Low, Age, Pre-
APRV MAP, BMI, APRV Initial T Low, APRV Initial T High, APRV Initial P High, 
Weight 
 
Table 13 summarizes the results of the multiple regression analysis to determine which are 
significant predictors of pre-APRV MSOFA score.  The regression results showed that the model 
fit of the regression model (F (10, 32) = 1.43, p = 0.21) generated was insignificant indicating 
that the regression model did not have an acceptable model fit.  The r-square value of the 
regression model was 0.31, which indicates a moderate effect size and that the combined effects 
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of all independent variables captured 31% of the variance in predicting the pre-APRV MSOFA 
score.  The investigation of the individual impacts showed that all independent variables of age (t 
(42) =1.01 , p = 0.32), height (t (42) = 1.02, p = 0.32), weight (t (42) =-0.87 , p = 0.39), BMI (t 
(42) = 0.94, p = 0.35), APRV MAP (t (42) = 0.99, p = 0.33), T high (t (42) = -0.03, p = 0.98), T 
low (t (42) = 1.37, p = 0.18), P high (t (42) = 0.04, p = 0.97), P low (t (42) = 1.11, p = 0.27), and 
MAWP (t (42) = -0.18, p = 0.86) were not significant predictors of pre-APRV MSOFA score.  
This was because all the p-values were greater than the level of significance value. 
Table 13: Multiple Regression Results of Predictors of Pre-APRV MSOFA Score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 (Constant) -23.17 26.86   -0.86 0.40 
Age 0.03 0.03 0.16 1.01 0.32 
Height 0.41 0.41 0.64 1.02 0.32 
Weight -0.06 0.07 -1.24 -0.87 0.39 
BMI 0.43 0.46 1.13 0.94 0.35 
Pre-APRV MAWP 0.09 0.09 0.17 0.99 0.33 
APRV Initial T High -0.01 0.24 -0.01 -0.03 0.98 
APRV Initial T Low 0.91 0.67 0.26 1.37 0.18 
APRV Initial P High 0.01 0.33 0.01 0.04 0.97 
APRV Initial P Low 0.14 0.13 0.21 1.11 0.27 
APRV Initial MAWP -0.06 0.32 -0.07 -0.18 0.86 
Note.  F(10, 32) = 1.43, p = 0.21, R Square (R2) = 0.31, n = 42 
a. Dependent Variable: APRV initial MSOFA Score 
b. Predictors: (Constant), APRV Initial MAWP, Height, APRV Initial P Low, Age, Pre-
APRV MAP, BMI, APRV Initial T Low, APRV Initial T High, APRV Initial P High, 
Weight 
 
          Post-APRV Results 
For the pre-APRV data, the independent variables included the age, height, weight, BMI, 
APRV duration, T high, T low, P high, P low, and MAWP.  Tables 14 through 17 summarizes 
the results of the different multiple regression analyses to determine which post-APRV scores of 
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the independent variables are significant predictors of the post-APRV scores of P/F ratio, OI, 
OSI, and MSOFA. 
Table 14 summarizes the results of the multiple regression analysis to determine which are 
significant predictors of post-APRV P/F Ratio.  The regression results showed that the model fit 
of the regression model (F (10, 9) = 0.65, p = 0.75) generated was insignificant indicating that 
the regression model did not have an acceptable model fit.  The r-square value of the regression 
model was 0.42, which indicates a moderate effect size and that the combined effects of all 
independent variables captured 42% of the variance in predicting the post-APRV P/F Ratio.  The 
investigation of the individual impacts showed that all independent variables of age (t (19) = -
0.25, p = 0.81), height (t (19) = -0.68, p = 0.51), weight (t (19) = 0.49, p = 0.64), BMI (t (19) = -
0.31, p = 0.77), APRV duration (t (19) = -0.92, p = 0.38), T high (t (19) = 0.76, p = 0.47), T low 
(t (19) = 0.38, p = 0.71), P high (t (19) = 0.29, p = 0.78), P low (t (19) = -0.39, p = 0.71), and 
MAWP (t (19) = -0.09, p = 0.93) were not significant predictors of post-APRV P/F Ratio.  This 
was because all the p-values were greater than the level of significance value. 
Table 14: Multiple Regression Results of Predictors of Post-APRV P/F Ratio  
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 (Constant) 818.64 1105.38   0.74 0.48 
Age -0.40 1.60 -0.08 -0.25 0.81 
Height -12.05 17.71 -0.76 -0.68 0.51 
Weight 1.83 3.71 1.22 0.49 0.64 
BMI -6.64 21.75 -0.70 -0.31 0.77 
APRV Duration -4.04 4.39 -0.28 -0.92 0.38 
Post-APRV T high 9.04 11.87 0.33 0.76 0.47 
Post-APRV T low 14.75 38.50 0.15 0.38 0.71 
Post-APRV P high 1.43 4.92 0.10 0.29 0.78 
Post-APRV P low -2.20 5.63 -0.13 -0.39 0.71 
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Post-APRV 
MAWP 
-0.32 3.70 -0.03 -0.09 0.93 
Note.  F(10, 9) = 0.65, p = 0.75, R Square (R2) = 0.42, n = 19 
a. Dependent Variable: Post-APRV P/F ratio 
b. Predictors: (Constant), Post-APRV MAWP, APRV Duration, Height, Age, Post-APRV P 
low, Post-APRV T low, Post-APRV P high, BMI, Post-APRV T high, Weight 
 
Table 15 summarizes the results of the multiple regression analysis to determine which are 
significant predictors of post-APRV OI.  The regression results showed that the model fit of the 
regression model (F (10, 9) = 1.40, p = 0.31) generated was insignificant indicating that the 
regression model did not have an acceptable model fit.  The r-square value of the regression 
model was 0.61, which indicates a strong effect size and that the combined effects of all 
independent variables captured 61% of the variance in predicting the post-APRV OI.  The 
investigation of the individual impacts showed that all independent variables of age (t (19) = -
0.53, p = 0.61), height (t (19) = 1.69, p = 0.13), weight (t (19) = -1.31, p = 0.22), BMI (t (19) = 
1.19, p = 0.26), APRV duration (t (19) = 0.96, p = 0.36), T high (t (19) = -0.42, p = 0.68), T low 
(t (19) = -0.39, p = 0.71), P high (t (19) = -0.71, p = 0.50), P low (t (19) = 0.82, p = 0.43), and 
MAWP (t (19) = 1.02, p = 0.33) were not significant predictors of post-APRV P/F Ratio.  This 
was because all the p-values were greater than the level of significance value. 
Table 15: Multiple Regression Results of Predictors of Post-APRV OI 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 (Constant) -282.92 179.02   -1.58 0.15 
Age -0.14 0.26 -0.15 -0.53 0.61 
Height 4.84 2.87 1.55 1.69 0.13 
Weight -0.79 0.60 -2.66 -1.31 0.22 
BMI 4.20 3.52 2.22 1.19 0.26 
APRV Duration 0.68 0.71 0.24 0.96 0.36 
Post-APRV T high -0.81 1.92 -0.15 -0.42 0.68 
Post-APRV T low -2.41 6.24 -0.12 -0.39 0.71 
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Post-APRV P high -0.57 0.80 -0.19 -0.71 0.50 
Post-APRV P low 0.75 0.91 0.23 0.82 0.43 
Post-APRV MAWP 0.61 0.60 0.28 1.02 0.33 
Note.  F(10, 9) = 1.40, p = 0.31, R Square (R2) = 0.61, n = 19 
a. Dependent Variable: Post-APRV OI 
b. Predictors: (Constant), Post-APRV MAWP, APRV Duration, Height, Age, Post-
APRV P low, Post-APRV T low, Post-APRV P high, BMI, Post-APRV T high, Weight 
 
 
Table 16 summarizes the results of the multiple regression analysis to determine which are 
significant predictors of post-APRV OSI.  The regression results showed that the model fit of the 
regression model (F (10, 59) = 3.33, p = 0.002) generated was significant indicating that the 
regression model has an acceptable model fit.  The r-square value of the regression model was 
0.40, which indicates a moderate effect size and that the combined effects of all independent 
variables captured 40% of the variance in predicting the post-APRV OSI.  The investigation of 
the individual impacts showed that that only the post-APRV MAWP (t (60) = 2.98, p < 0.001) 
was a significant predictor of post-APRV OSI.  This was the only p-value less than the level of 
significance value.  Investigation of the unstandardized beta coefficient value showed that post-
APRV MAWP positively predicted post-APRV OSI.  A one score increase in post-APRV 
MAWP will result to a 0.54 increase in the post-APRV OSI.  This means that the higher the post-
APRV MAWP will result in a higher post-APRV OSI. 
Table 16: Multiple Regression Results of Predictors of Post-APRV OSI 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 (Constant) -59.85 34.74   -1.72 0.09 
Age -0.03 0.04 -0.07 -0.60 0.55 
Height 0.91 0.52 0.75 1.74 0.09 
Weight -0.16 0.08 -1.55 -1.94 0.06 
BMI 0.89 0.51 1.27 1.73 0.09 
APRV Duration -0.14 0.13 -0.13 -1.08 0.29 
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Post-APRV T high 0.03 0.33 0.01 0.10 0.92 
Post-APRV T low 0.03 1.51 0.00 0.02 0.98 
Post-APRV P high 0.26 0.20 0.19 1.32 0.19 
Post-APRV P low 0.25 0.16 0.18 1.58 0.12 
Post-APRV MAWP 0.54 0.18 0.43 2.98 0.00* 
Note.  F(10, 59) = 3.33, p = 0.002, R Square (R2) = 0.40, n = 60 
a. Dependent Variable: Post-APRV OSI 
b. Predictors: (Constant), Post-APRV MAWP, APRV Duration, Height, Age, Post-APRV P 
low, Post-APRV T low, Post-APRV P high, BMI, Post-APRV T high, Weight 
*Significant at level of significance of < 0.05 
 
Table 17 summarized the results of the multiple regression analysis to determine which are 
significant predictors of post-APRV MSOFA score.  The regression results showed that the 
model fit of the regression model (F (10, 40) = 2.03, p = 0.06) generated was insignificant 
indicating that the regression model did not have an acceptable model fit.  The r-square value of 
the regression model was 0.34, which indicates a low effect size and that the combined effects of 
all independent variables captured 34% of the variance in predicting the post-APRV MSOFA 
score.  The investigation of the individual impacts showed that post-APRV P high (t (50) = 2.35, 
p = 0.02) and P low (t (50) = 2.39, p = 0.02) were significant predictors of post-APRV MSOFA 
score.  These were the only p-values less than the level of significance value.  Investigation of 
the unstandardized beta coefficient value showed that both post-APRV P high and P low 
positively predicted post-APRV MSOFA score.  A one score increase in post-APRV P high will 
result to a 0.29 increase in the post-APRV MSOFA score.  A one score increase in post-APRV P 
low will result to a 0.26 increase in the post-APRV MSOFA score.  This means that the higher 
the post-APRV P high and P low will result in a higher post-APRV MSOFA score. 
Table 17: Multiple Regression Results of Predictors of Post-APRV MSOFA Score 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
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1 (Constant) -22.95 21.02   -1.09 0.28 
Age 0.02 0.03 0.09 0.61 0.55 
Height 0.35 0.32 0.53 1.08 0.29 
Weight -0.06 0.05 -1.04 -1.16 0.26 
BMI 0.44 0.31 1.18 1.40 0.17 
APRV Duration -0.01 0.09 -0.02 -0.15 0.88 
Post-APRV T high -0.20 0.20 -0.15 -1.01 0.32 
Post-APRV T low -0.55 1.25 -0.07 -0.44 0.66 
Post-APRV P high 0.29 0.13 0.37 2.35 0.02* 
Post-APRV P low 0.26 0.11 0.33 2.39 0.02* 
Post-APRV MAWP 0.01 0.11 0.01 0.05 0.96 
Note.  F(10, 40) = 2.03, p = 0.06, R Square (R2) = 0.34, n = 50 
a. Dependent Variable: Post-APRV MSOFA Score 
b. Predictors: (Constant), Post-APRV MAWP, APRV Duration, Height, Age, Post-APRV P 
low, Post-APRV T low, Post-APRV P high, BMI, Post-APRV T high, Weight 
*Significant at level of significance of < 0.05 
 
 Given that this study examined both absolute values and changes in all clinical outcome 
scores (P/F ratio, OI, OSI, and MSOFA) at two time points (T0 and T’X’), there was the 
potential for subjects to continue receiving APRV beyond the recorded time.  Additionally, not 
all subjects had available metrics to calculate both pre-APRV or post-APRV dependent 
variables.  
Summary 
 The data bears clinical implication in several ways.  One can appreciate that the overall 
sample may not render an accurate representation of the entire patient population nor does it 
necessarily exactly align with the average expectation in what is seen during local patient care.  
However, study results may offer insight into better practice.  Certain findings such as the effect 
of MAWP on certain clinical outcomes can be viewed as indirectly supporting the original 
hypothesis.  As it is well-known that I-time affects MAWP (Burchardi, 1996), this study 
confirmed that I-time is a setting of great importance.  Likewise, particular settings can directly 
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or indirectly affect short term clinical outcomes and arguably end organ function.  In the 
upcoming Chapter 5, specific clinical implications and relevancy to bedside care are discussed in 
detail.  It is important to note that results from this study should only be interpreted as presented, 
although there is an alignment with the theory from prior studies of APRV as a mode of 
stabilization for alveolar units.   
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Chapter 5: Discussion 
Introduction to Chapter 5 
 This study yielded both expected and unforeseen results.  It was to be assumed, based 
upon the small pilot performed prior to this larger-scale study, that results of this study would 
have been relatively concurrent or, at the least, continuing in alignment with the results of the 
pilot.  However, there are a few items of particular interest discussed in detail within this chapter.  
As the results are further presented and discussed, the investigator urges the reader to be aware 
of variables that have not necessarily been linked into the study but may be thought of as an 
influencer nonetheless.  The study may be underpowered given the relatively small sample size, 
but there are specific results worth noting that bare both statistical as well as clinical 
significance.   
 Various limitations apply to this study and will be discussed.  Several interesting findings 
have immediate applicability to current bedside care and allowed the investigator immense 
insight into particular practice patterns at the large academic medical center of study.  All 
retrospective data was treated as such, and all results were appraised by the investigator in the 
capacity of a doctoral-candidate level researcher and licensed, practicing Respiratory Therapist.  
The following results and accompanying interpretations are meant to provide the reader with a 
detailed understanding reflective of the investigator’s overall body of work.  
Discussion and Interpretation of Results 
Demographics 
 At the large academic medical center in which the study was conducted, based upon 
observation of the local demographics and patient population, it was expected to have sampled a 
cohort comparable to the overall general demographic.  However, study results yielded a 
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predominant Caucasian sample population as opposed to the more prevalent African American 
patient population.  It was not necessarily expected to have a predominant middle-aged sample 
nor was it expected that only 68 subjects could be identified over a 3-year period from the EHR 
archives, having received APRV for a minimum of 8 hours consecutively.  It is suspected there 
were undoubtedly potential subjects that were not captured during the initial data extraction by 
the UH IT team, but this is only speculation based upon the experience of the investigator in 
having cared for multiple patients over many years that consistently received APRV.  In this 
study, a majority of the subjects were cared for in the SICU; however, it should be noted that 
patients are often managed by the MICU service in the SICU environment.  This management 
could be a confounder in delineating PPV management preferences among the ICUs.   
Clinical Data 
 There was some difficulty acquiring all pertinent ventilator settings for some subjects as 
documentation was variable and occasionally lacking.  Upon contacting the RT department, it 
was found that no specific policy existed for documentation requirements of ventilator settings 
and parameters.  Moreover, it was noted upon re-review of subject’s EHRs that certain subjects 
had emergent events that necessitated rapid intubation and placement on PPV.  Other subjects 
were removed from APRV prior to the 24-hour target period based upon varying provider 
preferences.  Certain documented APRV settings revealed that several patients were only placed 
on APRV as a mode but did not have technical APRV implemented as originally purposed (i.e., 
I-time < 1 sec; I:E < 1:1).    
 On average, subjects received higher MAWP during APRV as compared to their prior 
PPV mode, but this did not result in overall higher subject SpO2 after APRV initiation.  This 
may be attributed to the fact that some subjects were placed on APRV as a rescue mode while 
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their clinical status was deteriorating.  Likewise, as evidenced by the pre-APRV MSOFA scores, 
end organ dysfunction may have been developing simultaneously.  Although average I-time (T 
high) during APRV for subjects was 6.3 seconds, there was disparity among the overall sample 
(min-max: 0.9 sec – 11.0 sec).  This could be attributed to provider preference or even misplaced 
caregiver documentation, exchanging I-time with the inspiratory ratio of the I:E.  In summary, it 
was assumed that all EHR documentation was accurate and all data manually entered was done 
so without error.  
Outcomes of Interest 
 For the main study dependent variables, referred to as short-term clinical outcomes, all 
showed improvement.  The change in P/F ratio, OI, OSI, and MSOFA were all in a desirable 
direction with a statistically significant change in P/F ratio and OSI.  Because the number of 
subjects ascribed to each group was highly variable, there may have been a greater effect 
appreciated if a larger number of subjects were sampled.  There was difficulty acquiring a PaO2 
on most subjects as this metric is only available through an arterial blood gas (ABG) procedure.  
A majority of patients do not receive daily ABGs nor did the time of onset of APRV or cessation 
thereof necessarily coincide with the timeframe in which the ABG may have been acquired 
according to typical institution protocol or ordering provider preference.  Moreover, as prior 
outlined in the “Special Considerations” section, other data required for calculation of dependent 
variables was lacking owing to smaller sample size of the individual groupings for pre-APRV 
and post-APRV change scores. 
 The P high, P low, the MAWP, and subject’s BMI each impacted one or more clinical 
outcomes.  It is unknown whether the impact was a function of a stand-alone variable or whether 
a conglomerate of several entities rendered the effect.  However, it is well-known in clinical 
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practice that, mathematically, P high and P low directly affect MAWP.  It is also known that 
patients with higher BMI typically have less desirable clinical outcomes and higher mortality 
overall (Calle, Thun, Petrelli, Rodriguez, & Heath, 1999).  The study revealed that a lower 
setting for P high, P low, T low, and overall lower target MAWP were associated with a better 
OI, OSI, and MSOFA score.  In consideration of MSOFA score as a validated indicator of acuity 
and predictor of mortality, patients in this study tended to be at moderate risk overall.  This may 
have affected outcomes unrelated to PPV management.   
 The regression analysis identified P low as a significant predictor of pre-APRV P/F ratio 
(not causal).  MAWP was identified as a significant predictor of post-APRV OSI (contributing 
factor).  Finally, P high and P low were identified as significant predictors of post-APRV 
MSOFA scores (contributing factor).  The results of the regression revealed that the higher the P 
low, the lower resulting P/F ratio (undesirable), while the higher the MAWP, the higher the OSI 
(undesirable).  Additionally, the higher the P high and P low, the higher the MSOFA score 
(undesirable).  In summary, both P high and P low should be kept as low as possible while a 
higher MAWP should only be targeted in order to increase OSI. 
 The study dependent variables were considered surrogates for short-term clinical 
outcomes and should only be regarded as such.  There is no one metric that absolutely represents 
a desirable clinical outcome.  Likewise, there is no known PPV setting or parameter that is an 
exclusive influencer of a short-term clinical outcome.  It would have been highly valuable to be 
able to follow each subject’s entire course of care in order to investigate whether change scores 
for P/F ratio, OI, OSI, and MSOFA metrics continued to trend in the same direction as in this 
retrospective analysis.  As well, a prospective study might offer an opportunity in which to 
	 86	
guarantee the acquisition of certain parameters, such as PaO2, with the target of building a 
larger, more consistent sample size for each outcome.  
APRV Current Considerations 
 A recent study confirmed that there is variable opinion on APRV management among 
PPV practitioners (Miller et al., 2017).  In the current literature, however, APRV is still 
recommended as a protective mode of PPV, favored above a majority of traditional modes for 
ARDS management (Perinel-Ragey, Baboi, & Guerin, 2017).  Perhaps the greatest attraction of 
APRV use is the ability to limit cyclic opening and closing of lung units, which allow more 
stability and the implementation of optimal PEEP by means of preventing de-recruitment during 
the expiratory phase, and not by PEEP setting alone, such as in a traditional mode of PPV.  A 
recent review by Niemen et al. (2017) suggests that APRV allows for personalization of PEEP, 
generating intrinsic PEEP in order to stabilize the lung and avoid VILI (Nieman et al., 2017).  It 
will be interesting to monitor for future studies in this area of research to appreciate any 
developments in suggested starting parameters for APRV initiation of more specific management 
strategies as a whole.  
 APRV, in general, is thought to reduce overall lung stress and strain by diminishing 
dynamic alveolar heterogeneity (Kollisch-Singule et al., 2016).  Moreover, a 2013 systematic 
review by Andrews et al. suggested that, in high risk patients, the early application of APRV 
may prevent progression to ARDS (Andrews et al., 2013).  One of the most well-known 
published studies of APRV cites that “APRV seems to have a similar safety profile to low tidal 
volume ventilation” (Maxwell et al., 2010), but it is not recommended to utilize APRV as a 
rescue mode.  Additionally, the originator of APRV, along with colleagues, recommends the 
incorporation of a “physiology driven” approach with individualized ventilator setup in addition 
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to adopting a view that P High and T High should not necessarily be considered concurrent 
entities (Evans, Stawicki, Eiferman, Reilley, & Downs, 2011).  Although almost no studies have 
addressed specific initial settings, Madden et al. recommends setting a Plow of 0 cmH2O in order 
to optimize CO2 clearance (Madden et al., 2016), but this does not address oxygenation.   
Implications for Practice 
  Currently, there is a lack of agreement among ordering providers, institutional protocol, 
and RTs, alike, on when and how PPV should be implemented.  There is also no consensus, 
specifically, on how PPV should be managed (Miller et al., 2017).  This study revealed a 
congruency with this ideal.  Results were not absolutely conclusive based upon a most likely 
underpowered sample.  Moreover, a study of this kind requires one to evaluate all results in 
perspective for which population was evaluated.  Not all bedside practice involves a patient 
population akin to subjects of this study.  However, patients at other institutions with comparable 
acuity and risk levels may greatly benefit from specific APRV employment over longer periods 
of time as evidenced by the appreciable improvement seen for all dependent variables in this 
study.   
 It was evident that no particular standard for ordering APRV or managing APRV settings 
existed, either between different ICUs or among the same ICU.  It seemed as if the ordering 
provider had the greatest bearing on initial settings implementation, but it is difficult to identify a 
trend with an N of 68.  Certain covariates, as well as individual comorbidities and pre-existing 
conditions, were unable to be evaluated.  Other potential confounders were identified but not 
tested, such as the fact that subjects had highly differing precipitating events that led to APRV 
initiation and a highly variable time delay between intubation and APRV implementation.  
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Furthermore, it was empirically noted that certain providers ordered similar APRV settings on all 
patients, regardless. 
 Our local institution should greatly benefit from the findings of this study, in that it seems 
as if a lower P high, P low, and MAWP could be attributed to a more positive short-term clinical 
outcome based upon the dependent variables of this study.  Although I-time (T high) did not 
render a statistically significant relationship with any of the dependent variables, one should 
appreciate that a lower P high was attributed to a lower (more desirable) MSOFA score.  It has 
long been known that MAWP affects oxygenation and that I-time directly affects MAWP during 
PPV (Boros, 1979).  Also, longer inflation times allow for maintenance of MAWP at lower peak 
pressures while decreasing cyclic opening and closing of lung units (E. G. Daoud et al., 2012).  
In this study, subjects received a highly variable I-time, and it would be recommended for future 
similar studies that outliers be discarded to prevent confounding.  
 Overall, this study offers insight to all clinicians that manage PPV, especially those who 
regularly manage APRV.  Based upon the study results, the investigator recommends the 
following during APRV initiation and management: 1) utilize the lowest possible P high and P 
low to achieve acceptable oxygenation and CO2 clearance, 2) closely attend to T low, titrating as 
necessary but maintaining IRV, and 3) allow for lowest possible MAWP while allowing for 
adequate inflation and acceptable oxygenation.   
Implications for Further Research 
 Further research is certainly warranted to explore the deeper concepts surrounding APRV 
implementation and prolonged application of this specialized mode.  Although APRV is an 
established protective mode of PPV, a majority of studies have only utilized analogue models, 
animals, or a small population of particularly specific subjects.  This study gives insight into a 
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small, moderate risk population of patients managed on APRV for a short period of time.  There 
remains much opportunity for more exploration of the topic.  Ideally, a randomized control trial 
of a larger cohort should be identified in which APRV was maintained for at least 24 hours 
consecutively.  A prospective study may allow for better congruency between true SOFA scores 
and other validated metrics within the realm of a pre-APRV and post-APRV evaluation. 
 It is still unknown whether specific APRV settings directly affect long-term outcomes 
and mortality.  Additionally, though the results of this study showed that P high, P low, and 
MAWP affect a short-term clinical outcome, data is still lacking as to what particular settings 
might be recommended as starting points in the general adult population.  It is important to note 
that applicability to a general population of those receiving PPV has yet to be determined.  
Moreover, a larger study, templated and based on this study’s methodology, should be 
considered in order to appreciate a greater effect should one be realized.   
Limitations and Delimitations 
 Several limitations and delimitations were noted in this study.  Arguably, the greatest 
limitation of this study is that it is underpowered given the yield of only 68 subjects from a 
retrospective search of the EHR within a 3-year period.  Because all data acquired was gleaned 
retrospectively, a major limitation was the fact that the EHR system was only recently adopted, 
beginning circa October, 2013.  This timeframe absolutely limited the timeframe in which data 
could easily be acquired in a comprehensive manner without data mining through traditional 
paper charts.  In the future, it is recommended to target a longer timeframe in order to capture a 
greater cohort of subjects.   
 Even after planning in advance and working directly with the UH Information Office, it 
was initially difficult to identify all particular patients that received APRV for at least exactly 12-
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24 hours consecutively.  This timeframe limitation contributed to the overall low sample 
population.  It was noted during the review of raw data from the original full EHR that there was 
a lack of documentation on ventilator flowsheets with occasional missing parameters and 
settings, highly dependent upon the timeframe in which the original input occurred and also 
variable according to the healthcare provider documenting the events. 
 In reviewing the actual EHR to manually extract additional information to satisfy the 
missing fields from the initial report, there was some difficulty in identifying lab values exactly 
concurrent with onset, cessation, or APRV, so the investigator set a timeframe range allowable 
for recording.  As previously mentioned, PaO2 was also not commonly acquired as it is not 
standard practice when patients are relatively stable and have available non-invasive SpO2 
monitoring.   
Recommendations 
 It is recommended that future investigation related to this study topic evaluate a greater 
timeframe in order to capture a potentially larger sample population.  Additionally, it may be 
worthwhile to develop a prospective study evaluating this same ideal as well as evaluate a 
broader scope of clinical outcomes both short term and long term.  A prospective study would 
allow more control over time delay for APRV initiation, total time on APRV, and congruency 
with lab results concurrent with particular outcomes of interest.   
 A multi-center, prospective study should be designed that would include a large number 
of subjects that could be investigated in a more controlled manner.  A study to include more time 
aligned lab and other parameter acquisition with concurrent APRV initiation is recommended.  
Additionally, a study that reports outcome metrics after a more consistent APRV dosing (i.e., 
each subject receiving 24-48 hours continuous APRV) may render more appreciable results.  In 
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summary, no study design is without flaw, but the more variables that are accounted for and 
controlled, the higher likelihood results would be applicable to a more general population. 
Summary 
 In conclusion, there is no stand-alone metric able to predict an absolute clinical outcome.  
Neither can the implications of this study be applied explicitly to similar populations.  This study 
simply suggests that there may be an ideal way to ventilate patients in the APRV mode under 
certain conditions.  A larger study to include more subjects followed over a longer period of time 
is recommended.  The incorporation of other outcome measures would also be necessary in order 
to assume more comprehensively the P/F ratio, OI, OSI, and MSOFA scores that were most 
affected by the specific variables identified in the correlational matrixes, bivariate analyses, and 
regression analysis.   
 The identified predictors of P high, P low, and MAWP impacting the short-term clinical 
outcomes should only be considered in alignment with and within the parameters of this specific 
study.  In order to account for covariates, such as those associated with particular comorbidities 
as sepsis, organ failure, and genetic predisposition, a more in-depth evaluation of these particular 
variables would be necessary.   
 Although the EHR is considered an accurate database of patient information, there is 
potential for human error in the recording process.  This study gives insight into the potential of 
exploring preferred ways in which to artificially ventilate patients, withholding the compounding 
of stress, strain on the lungs, and the long-term effects thereof.  It should be noted that with 
longer I-times, inflation pressures are expected to be slightly lower as compared with shorter I-
times when pressure is applied over less time.  The ordering provider ultimately influences what 
settings are initiated at onset of APRV.  Likewise, the managing medical team, overall, certainly 
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impacts the patient’s course of care and may influence the manipulation of mechanical 
ventilation.    
 This study confirms that settings for APRV should not be chosen arbitrarily and that the 
purposeful application of APRV could have both positive and negative effects that influence 
more than just oxygenation.  In alignment with the prior published recommendations of both 
Habashi and Modrykamien et al., the investigator would not disagree that it is still a good 
strategy to set T low to target inducement of auto PEEP with an initial P low setting of 0 cmH2O 
(Habashi, 2005; Modrykamien et al., 2011).  However, the results of this dissertation study 
would suggest also that both P high and MAWP should be applied judiciously and maintained as 
low as possible in order to promote better short-term clinical outcomes.   
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Appendix: 
Appendix A: Data Collection Tool 
*All	missing	(undocumented)	fields	will	be	designated:	“#”	
MRN:	 	 	 ______________________________	
Adm	Date/Time:	 _______________;	________	
Disch	Date/Time:					_______________;	________	
DOB:    _______________;  __________ (Age at onset of APRV: yrs) 
Sex:   Male;   Female    Race: ________   
Height (flowsheets, tabs):  __________ (in) 
Weight (flowsheets, tabs):  __________ (lbs) 
Dx ARDS? (ICD-9: 518.82; ICD-10: J80): Y(1)/N(2)  
Provider # during APRV management: ______________ 
ICU stay during APRV management: MICU (1), SICU (2), Neuro ICU (3), Other (4) 
 
Time from intubation to initiation of APRV (hrs): _____ . __ 
Respiratory status immediately prior to initiation of APRV: 
Prior Vent mode: PRVC/PCVG (1);   PC (2);   PS/CPAP (3);  VC (4);  unknown (5): ________ 
Pre-APRV, Main setting: (PC level, Vt, PS): _______________________ 
FiO2: ________ (%) 
PEEP:  ________ (cmH2O) 
PIP: ________ (cmH2O) 
MAP: ________ (cmH2O) 
SpO2: ________ (%) PaO2: ________ (mmHg) 
 
APRV initial settings: 
I:E: ________ 
FiO2: ________ (%) 
T high: ________ (secs)   Phigh:   ________ (cmH2O)  HR: _____ (bpm) 
T low:   ________ (secs)      Plow:   ________ (cmH2O)  RR: _____ (bpm) 
PIP:  ________ (cmH2O)  MAWP:  ________ (cmH2O)  
RR spont:  ________ (bpm)    
RR: total:  ________ (bpm)  Ve:   ________ (l/min) 
Vt exhaled:  ________ (mls)   PaO2:  __________ (mmHg);  Time: ________ 
Vt spont:  ________ (mls)  SpO2:  ___________(mmHg);   Time: ________ 
 
Variables post-APRV at least 24 hours: total hours on APRV when below values recorded: ____ 
I:E: ________ 
FiO2: ________ (%) 
T high: ________ (secs)   Phigh:   ________ (cmH2O)  HR: _____ (bpm) 
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T low:   ________ (secs)      Plow:   ________ (cmH2O)  RR: _____ (bpm) 
PIP:  ________ (cmH2O)  MAWP:  ________ (cmH2O)  
RR spont:  ________ (bpm)    
RR: total:  ________ (bpm)  Ve:   ________ (l/min) 
Vt exhaled:  ________ (mls)   PaO2:  __________ (mmHg);  Time: ________ 
Vt spont:  ________ (mls)  SpO2:  ___________(mmHg);   Time: ________ 
MSOFA Score at initiation of APRV: 
SpO2:  ________ (%) 
FiO2:  ________ (%) 
(Liver): Presence of documented scleral icterus or jaundice ___ yes    ___ no 
Bilirubin: ________ (mg/dL) 
MArtBP: ________ (mmHg)   
Hypotn level: ________ (Score*) 
*no hypot = 0; MAP<70 = 1; on vasopressors, dopamine<5µg/kg/min or dobutamine any dose = 2; 
dopamine >5µg/kg/min or Epi/Norepi<0.1µg/kg/min = 3;  dopamine > 15µg/kg/min or 
Epi/Norepi>0.1µg/kg/min = 4) 
GCS:  ________  
Creatinine: ________ (level) 
Creatinine: ________ (Score*) 
*Cr<1.2mg/dL (<106µmol/L) = 0; Cr 1.2-1.9 mg/dL (106-168 µmol/L) = 1; Cr 2.0-3.4mg/dL (177-
301µmol/L) = 2; Cr 3.5-4.9mg/dL (309-433 µmol/L) Or UO<500ml/day = 3; Cr>5.0mg/dL 
(>442µmol/L) = 4 
SOFA (Sequential Organ Failure Assessment) Score after on APRV at least 24 hours:  
total hours on APRV when below values recorded: ____ 
SpO2:  ________ (%) 
FiO2:  ________ (%) 
(Liver): Presence of documented scleral icterus or jaundice ___ yes    ___ no 
Bilirubin: ________ (mg/dL) 
MArtBP: ________ (mmHg)   
Hypotn level: ________ (Score*) 
*no hypot = 0; MAP<70 = 1; on vasopressors, dopamine<5µg/kg/min or dobutamine any dose = 2; 
dopamine >5µg/kg/min or Epi/Norepi<0.1µg/kg/min = 3;  dopamine > 15µg/kg/min or 
Epi/Norepi>0.1µg/kg/min = 4) 
GCS:  ________  
Creatinine: ________ (level) 
Creatinine: ________ (Score*) 
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*Cr<1.2mg/dL (<106µmol/L) = 0; Cr 1.2-1.9 mg/dL (106-168 µmol/L) = 1; Cr 2.0-3.4mg/dL (177-
301µmol/L) = 2; Cr 3.5-4.9mg/dL (309-433 µmol/L) Or UO<500ml/day = 3; Cr>5.0mg/dL 
(>442µmol/L) = 4 
 
 
